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Cardiovascular diseases (CVD) are the leading cause of mortality in the world. Responsible for 
nearly 1/3 of all deaths globally, CVD poses extreme public health challenges and a growing economic 
burden. Atherosclerosis is fundamental to CVD, and is characterized by the accumulation of plaque within 
arterial blood vessels. Atherosclerotic plaques are the result of lipid deposition in the subendothelial 
space, which initiates monocyte infiltration and formation of lipid-laden foam cells derived from 
macrophages. The inflammatory cascade that follows, promotes plaque formation and development. 
Disease progression ultimately leads to a number of atherosclerotic pathologies including myocardial 
infarction and ischemic stroke. Clearly, our greatest efforts are required in exploring novel therapeutic 
perspectives that ameliorate inflammation and prevent dysfunctional cholesterol metabolism. 
 My work has been directed at investigating the potential role of macrophage chitotriosidase-1 
(CHIT1) overexpression in dampening production of pro-inflammatory cytokines and inhibiting 
macrophage foam cell formation. We generated an atherosclerotic mouse model constitutively 
overexpressing CHIT1 by crossing hyperlipidemic Ldl-r-/- mice with transgenic, CHIT1 overexpressing mice. 
We carried out in vitro experiments aimed at elucidating the effect of CHIT1 overexpression on 
macrophage inflammatory mechanisms, cholesterol metabolism, and invasion. In vitro, macrophage 
overexpression resulted in diminished mRNA transcription of important pro-inflammatory mediators and 
increased expression of cytokines involved in immune cell migration and anti-inflammatory processes. We 
also observed that CHIT1 overexpression in BMDM enhanced macrophage invasiveness. The CHIT1-
overexpressing, atherosclerotic mouse model (Ldlr-/--CHIT1-OE) facilitated a long-term in vivo mouse 
study. Animals in the study were fed a high-fat diet for 12 weeks which resulted in robust atherosclerotic 
progression. Although CHIT1 overexpression in Ldlr-/- mice did not affect plaque development when 
compared to control mice, we were able to observe significant differences in plaque morphology related 
to the deposition of ECM components. This unexpected finding may suggest that CHIT1 overexpression 
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affects plaque stability in atherosclerotic mice. The possibility of CHIT1 mediated athero-protection may 
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 CHAPTER 1: INTRODUCTION 
 
1.1 Cardiovascular disease burden 
Cardiovascular disease (CVD) is a term that describes a group of pathologies affecting the heart 
and blood vessels. Diseased and damaged blood vessels supplying the heart muscle, the brain, arms and 
legs, as well as myocardial and valvular damage manifests in specific etiologies. Coronary heart disease, 
cerebral vascular disease, peripheral artery disease, and others are extremely complex maladies 
associated with the more general CVD. 
CVD is the leading cause of mortality worldwide. In 2015, CVD claimed an estimated 17.7 million 
lives accounting for nearly 1/3 of all global deaths [1, 2]. In the United States alone approximately 801,000 
Americans die from heart disease each year. Responsible for 1 in every 3 deaths, CVD is the leading cause 
of death for both men and women in America [3]. 
1.1.2 Economic burden 
In 2015 the estimated global cost of CVD's in terms of lost productivity and healthcare expenses 
reached $906 billion [1]. According to the same metrics, the American Heart Association estimates that in 
2017 the economic burden of CVD in the United States is $306 billion. Advancements in medical 
technology, pharmaceuticals, and education have been integral to the declining CVD-related mortality 
rates among industrialized countries. The trend continues domestically where total mortality decreased 
3.79% between 2000-2011. However, this decline in mortality decelerated during 2011-2014 to just 0.23% 
[3]. It appears likely that while awareness of major cardiovascular risk factors like elevated cholesterol, 
hypertension, and smoking is increasing, they are also being replaced with other risk factors including 
obesity and diabetes. This disturbing trend is only compounded from an epidemiological fact that 
prevalence of CVD mortality is increasing among developing and low income countries. By 2030 the total 
economic burden felt worldwide is expected to meet or exceed $1 trillion [4]. 
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Through novel pharmaceutical therapies, innovative medical interventions, and greater 
awareness of personal risk factors, much progress has been made in the way of slowing mortality rates. 
Yet even now, the unprecedented cost of CVD in economic terms and more importantly in lives, implores 
us to seek a more profound and lucid comprehension of the molecular mechanisms involved in these 
diseases. Extensive research is required in the effort to ameliorate the extensive impact of CVD. 
1.2 Atherosclerosis-causes and risk factors 
Atherosclerosis describes a condition caused by the hardening of blood vessels due to the 
accumulation of lipids and immune cells within the lining of the vasculature [5]. These deposits develop 
into plaque over time which reduce blood vessel elasticity, compromise blood flow to the heart and brain, 
and are risk factors for thrombotic events [6, 7]. Occlusion of blood vessels can cause ischemia in the heart 
and brain as well as hypertension throughout the circulatory system. Elevated blood pressure loosens and 
dislodges parts of vulnerable plaques. When these fragments enter the circulation they can cause a 
blockage of vital arteries that supply the heart and brain resulting in myocardial infarction (MI) and stroke 
respectively [8, 9]. Although thrombolytic agents can be administered to patients experiencing stroke and 
MI in an effort to restore blood flow, it is often too late to avoid serious tissue or brain damage due mostly 
in part to lack of oxygen for extended periods of time [10]. 
Risk factors for atherosclerosis are generally classified into 2 categories: modifiable and non-
modifiable. Modifiable risk factors are environmental components which contribute to the development 
and progression of atherosclerosis [11, 12]. This type of risk factor includes: tobacco use, excessive alcohol 
consumption, sedentary lifestyle, hypercholesterolemia, hypertension, and metabolic conditions like 
diabetes mellitus and obesity [13-15]. Modifiable risk factors can be mitigated by the individual to prevent 
onset of atherosclerosis and/or impede its progress. Some risk factors however, cannot be altered with 
behavioral and lifestyle changes. Such risk factors are referred to as non-modifiable. Age, sex, and genetic 
traits comprise the category of non-modifiable risk factors. It has been well documented that risk for CVD, 
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and more specifically atherosclerosis, increases with age [16, 17]. Furthermore, men are more likely to be 
diagnosed with atherosclerosis at an earlier age than women [18, 19]. Studies suggest that at least some 
portion of gender-related risk factors for atherosclerosis can be attributed to physiological differences 
between men and women. For example, women tend to have a smaller carotid arteries exhibiting less 
plaque but a greater degree of stenosis possibly affecting angiogenesis and vascular remodeling [20]. 
Protective effects of hormones, like progesterone in women, may also contribute to the overall disparity 
in disease prevalence between the sexes [21, 22]. Others have demonstrated age-dependent effects of 
estrogen on atherosclerosis.. Administration of  17β-estradiol (E2) exhibited atheroprotective effects in 
young female mice and postmenopausal women. However, the same effect was not observed in older 
animals or postmenopausal women [23]. Preliminary studies with human macrophages show that 
estrogen receptor-α (ERα) is diminished in postmenopausal women compared to premenopausal women. 
Moreover, E2 hormone therapy beginning at menopause maintained ERα expression levels equivalent to 
premenopausal women. E2 also attenuated CRP dependent inflammatory responses in macrophages from 
premenopausal women but not in those derived from premenopausal women [24, 25].  
The genetic basis of CVD and coronary artery disease (CAD) is exhibited in rare Mendelian 
disorders that cause premature onset of the disease. The mutations mostly affect cellular lipid and 
cholesterol handling mechanisms. Examples of these heritable conditions are: familial 
hypercholesterolemia, familial defective APOB, APOA1 deficiency, and Tangier disease [26]. In recent 
years, genome-wide association studies (GWAS) have produced robust data and profound new insight 
into the genomic architecture of susceptibility to CVD [27]. Innovative genetic-epidemiological research 
utilizing GWAS has demonstrated an association between the regulation of specific genes like SORT1, 
which is implicated in the production of very low-density lipoprotein (VLDL), and ANRIL, a long non-coding 
RNA that appears to regulate genes that are adjacent to it [28]. A deficiency in one of these genes, Cdkn2a, 
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caused atherosclerotic lesion development and monocyte proliferation in a mouse model for 
atherosclerosis. 
1.3 Molecular mechanisms of atherosclerosis 
The development of atherosclerosis is initiated by elevated levels of circulating lipids in the 
vasculature. These lipids subsequently accumulate in the subendothelial space, beneath the intima where 
they become trapped within the extracellular matrix [29, 30]. Immobilized lipids can be modified by 
reactive oxygen species (ROS) and various enzymes [31]. Modified LDL activates smooth muscle cells 
(SMC) and endothelial cells (EC) lining the arteries, which under normal conditions are resistant to 
immune cell attachment, but begin to express adhesion molecules [32, 33]. Cell-surface proteins like 
vascular cell adhesion molecule (VCAM) and intracellular cell adhesion molecule (ICAM) facilitate 
monocyte tethering and diapedesis. Activated ECs also secrete chemokines like monocyte 
chemoattractant protein-1 (MCP-1), and the growth factors: macrophage-colony stimulating factor (M-
CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) [34].  
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(Gargiulo et al., 2016 International Journal of Molecular Sciences)  
Figure 1: Development and progression of atherosclerosis. 
(A) The initial stages of atherosclerosis are characterized by lesion formation, during which circulating LDL 
becomes trapped in the subendothelial ECM. (B) While sequestered, modification of LDL by reactive oxygen 
species (ROS) and various enzymes result in pro-inflammatory LDL particles. Endothelial cell activation, 
mediates the expression of adhesion molecules: P-selectin, VCAM-1, and ICAM-1. Activated endothelial 
cells subsequently initiate tethering and rolling of circulating monocytes through expression of P-selectin. 
After infiltrating the vascular intima, monocytes differentiate into macrophages that uptake and 
accumulate modified LDL. Macrophages, unable to maintain homeostatic cholesterol metabolism, become 
lipid-laden foam cells. Foam cell aggregation is referred to as a “fatty streak”. (C) Migration and 
proliferation of smooth muscle cells assist in the formation of a fibrous cap around the luminal side of the 
plaque, contributing to stability. Vulnerable plaques are prone to rupture and are characterized by 
defective efferocytosis, necrotic core development, and fibrous cap thinning. (D) Metabolically 
dysfunctional macrophages together with necrosis, release proteolytic enzymes thinning the protective 
fibrous cap. Matrix metalloproteinases (MMPs) produced by macrophages degrade various types of ECM 




In concert with adhesion molecules, chemokines and growth factors initiate recruitment, 
 infiltration, and proliferation of immune cells in the subendothelial space. A “fatty streak” is the earliest 
visual indication of lesion formation. Its appearance is the result of an innate immune response that 
recruits monocytes to regions of lipoprotein deposition [36]. Monocytes differentiate into macrophages 
within the intima and uptake modified lipoproteins. Enhanced phagocytosis and dysfunctional cellular 
metabolism of modified lipoproteins causes macrophages to become lipid-laden foam cells [37]. Foam 
cells and macrophages secrete inflammatory and cytotoxic substances as well as chemotactic cytokines 
thereby contributing to a chronic state of inflammation and macrophage activation [38]. The 
accumulation of modified lipoproteins, macrophage-derived foam cells, leukocytes, ECs and, SMCs over 
time results in atherosclerotic plaque formation [39]. Atheromatous plaques are initially stabilized by 
vascular smooth muscle cells. SMCs migrate and proliferate on the luminal aspect of the plaque where, 
over time, they form a fibrous cap [40]. In a stable plaque, the fibrous cap is reinforced with molecules 
that comprise the ECM like collagen and elastin [41]. Stability, however, can be compromised in vulnerable 
plaques where persisting high levels of circulating LDL exacerbates the inflammatory environment. 
Apoptosis and secondary necrosis of SMCs and lipid-laden foam cells signify early stages of necrotic core 
formation within the vulnerable plaque [42]. Dead cells, cell debris, and modified lipid deposits continue 
to promote necrotic core development eventually leading to acellular, lipid-rich regions in the plaque [43, 
44]. The cytotoxic milieu contained within, continues to activate infiltrating macrophages which, in turn, 
produce high levels of matrix-metalloproteinases (MMP). Thinning of the fibrous cap encapsulating 
vulnerable plaques are further destabilized by MMPs secreted by classically activated macrophages (M1), 
which degrades the collagen matrix leading to extreme weakening of the protective cap [45, 46]. MMPs 
are capable of completely degrading collagen and ECM, they are also implicated in modifications to 
soluble, cell surface proteins like cytokines and chemokines responsible for processes related to 
migration, proliferation, and death of immune cells [47]. Numerous publications have consistently 
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demonstrated the colocalization of MMPs with vulnerable plaques. MMP-knockout mice and transgenic 
mouse models that overexpress tissue inhibitors of MMPs (TIMP) exhibit diminished atherosclerosis [48, 
49]. Mechanical stress related to vascular stenosis, along with shear stress, and reduced elasticity can 
cause rupture of vulnerable plaques resulting in severe downstream pathologies including ischemic stroke 
and myocardial infarction [45, 50].  
1.4 Macrophages in Atherosclerosis 
(Hansson et al., 2011, Nature Immunology)  
Figure 2: Modified LDL uptake and inflammation. 
Modified LDL interacts with cell surface receptors triggering an inflammatory cascade. This results in the 
activation of various inflammatory pathways. Secretion of pro-inflammatory cytokines via IL-1β signaling 
and transcription of chemokines are examples of the downstream effects of modified LDL uptake by 
macrophages. Gene transcription of proteases contribute to plaque instability, while reactive oxygen 




Macrophage is the determinate cell type in all phases of atherosclerosis. During a typical immune 
response, recognition and phagocytosis of pathogens are the primary roles for resident and recruited 
macrophages. Clearance of the inflammatory stimuli and cessation of immune cell activity marks the 
resolution of acute inflammation. In atherosclerosis, however, macrophages display significantly altered 
functionality and behavior. Chronic inflammation is a hallmark of atherosclerosis. As a result of constant 
activation, macrophages exhibit extreme phenotypes of M1 polarization. So-called M1 macrophages 
display elevated lipid uptake by scavenger receptors; CD36 and SRA1. At the same time, activated 
macrophages secrete exaggerated amounts of cytokines and chemokines leading to further recruitment 
and polarization. Phagocytosis of modified LDL exposes the detrimental effects of improper lipid handling 
of macrophages in and around atherosclerotic plaques. Without adequate clearance of inflammatory LDL 
particles, dysfunctional macrophages, dead cells, and cell debris, accumulate in the microenvironment of 
an atherosclerotic plaque and promotes chronic inflammation largely through continuous infiltration, 


























(Colin et al., 2014, Immunol Rev.) 
Figure 3: Macrophage polarization in atherosclerosis. 
Under atherosclerotic conditions, monocytes are recruited to lesions sites where they differentiate into 
macrophages. Phenotypic heterogeneity of macrophages is dependent on their activation states. 
Classically activated, pro-inflammatory macrophages (M1) are the predominant cell type in atherosclerotic 
plaques. On the other hand, M2, Mhem, and M(Hb) macrophages are alternatively activated, exhibiting 
anti-inflammatory properties that are indicative of their atheroprotective nature. 
 
Macrophage polarization is a dynamic process that describes phenotypic changes in macrophage 
function related to inflammatory stimuli. The generalized M1/M2 nomenclature given to macrophages in 
differential inflammatory mechanisms was derived from the Th1 and Th2 lymphocyte classification 
relating to their respective pro-inflammatory and anti-inflammatory properties. In vitro polarization of 
macrophages is achieved through stimulation of toll like receptors (TLRs) by LPS and IFN-γ. M1-activated 
macrophages express a myriad of pro-inflammatory mediators. For example, inducible nitric oxide 
synthase (iNOS), tumor necrosis factor-alpha (TNF-α), proteolytic enzymes (i.e. MMPs), and cytokines of 
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the interleukin family: IL-1β, IL-6, and IL-12 [53]. Chemokines like Granulocyte-Macrophage-Colony 
Stimulating Factor (GM-CSF) and Monocyte Chemoattractant Protein-1 (MCP-1) are also secreted by M1 
macrophages, thereby contributing to the continued recruitment and retention of immune cells [54, 55]. 
Experimental evidence suggests that chronic overabundance of M1 macrophages alters inflammatory 
conditions in and around the atherosclerotic plaque micro-environment. M1 activated macrophages are 
associated with enhanced plaque progression, necrotic core development, and destabilization of the 
fibrous cap due to degradation of collagen and other ECM constituents [56-58].  
At the other end of the macrophage polarization spectrum are M2-activated macrophages. M2 
macrophages most often exhibit anti-inflammatory properties. Differentiation of M2 macrophages is 
achieved, in vitro, by stimulation with Th2 cytokines; IL-4 and IL-13, and the T regulatory cell (Treg) 
cytokine; IL-10  [53, 59]. The expression of anti-inflammatory mediators characterizes M2 activated 
macrophages. Increased expression of transforming growth factor-β (TGF-β), arginase-1 (Arg-1), mannose 
receptor-1, and IL-10 distinguish M2 macrophages from their pro-inflammatory, M1 counterpart [60, 61]. 
Increased collagen production is also a function of M2 activation as it contributes to wound healing and 
tissue repair [62]. Despite being largely antagonistic in function to M1 macrophages, the M2 phenotype 
is still in a state of “activation”. An M2 immune response is elicited by pathogens-associated molecular 
patterns (PAMPs), I.e. Allergic reactions and other instances of host defense against PAMP-containing 
pathogens as is the case in fungal infection and parasitic invasion [63, 64]. M1 and M2 immune functions 
differ in that the latter is typically less severe on host tissues and more chronic in duration, while the 
former is more acute, less discriminating, and under normal conditions resolves itself resulting in wound 
healing and tissue repair. It has been well-reported that populations of both M1 and M2 macrophages are 
present in and around the atherosclerotic plaque, and that phenotypic switching regularly occurs during 
plaque progression [65-67]. Over time, a disproportionate fraction of the macrophage population favors 
proliferation of M1 activation, increasing the risk for plaque rupture and thrombosis. M2 macrophages 
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are more prevalent in the early atheroma stages, however, in advanced plaques M2 macrophage 
abundance is directly related to plaque stability and asymptomatic plaque development [46, 68]. The 
polarization of macrophages, in vitro, using Th1 and Th2 cytokines effectively illustrates the plasticity of 
this cell type. Yet, it is also clear that, in vivo, the complex pathophysiology of atherosclerosis results in 
differentiation of diverse macrophage phenotypes. For example, a macrophage with an entirely unique 
activation profile from either M1 or M2 is induced by oxidized phospholipids. Termed Mox, it is a 
macrophage phenotype that is associated with increased expression of nuclear respiratory factor 2 
(NRF2)-dependent genes and reactive oxygen species [69]. In another phenotypically divergent instance, 
targeted deletion of Kruppel-like factor 4 (KLF4) resulted in enhanced Nf-κB activity and VCAM1 [70]. 
Significant downstream effects include inhibition of M2 and promotion of M1 activated macrophages, 
over-stimulated differentiation of M1 macrophages, and accelerated atherosclerosis progression in apoe-
/- mice. Understanding macrophage biology in the context of atherosclerosis is fundamental to 
ameliorating the development and progression of this metabolic inflammatory disease. Therefore, given 
the atherogenic conditions that ultimately become the chronic state of inflammation associated with 
atherosclerosis, there is a clearly relationship with perhaps the earliest determinant of inflammation; 
hypercholesterolemia, or elevated levels of circulating cholesterol. 
1.4.2 Lipid Homeostasis in Macrophages 
Plaque formation and development in atherosclerosis is driven by an inflammatory response to 
LDL particles trapped within the subendothelial space of the intima. While sequestered in the extracellular 
matrix, the LDL can be modified in such a way that macrophages are unable to properly metabolize the 
modified lipids. Increased uptake coupled with impaired efflux of cholesterol by macrophages disrupts 
reverse cholesterol transport (RCT) resulting in lipid-laden foam cells. Accumulation of foam cells is 
indicative of the pathophysiology associated with atherosclerosis [37].  
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Macrophage internalization of cholesterol is achieved through several different pathways. 
Modified lipoproteins are an inflammatory stimulus, which causes macrophages to express high levels of 
scavenger receptors that facilitate phagocytosis of oxidatively modified LDL. Moreover, macrophages 
possess receptors that also promote intracellular cholesterol accumulation [71, 72].  Scavenger receptors 
are located on the cell surface and mediate the functional mechanisms of phagocytosis, endocytosis, 
adhesion, and signaling [73]. Class A-1 scavenger receptor (SR-A1) was identified based on its ability to 
induce foam cell formation, and is highly expressed in macrophage-derived foam cells within 
atherosclerotic plaques [74]. Ligands for SR-A1 derive from a wide range of polyanionic macromolecules. 
SR-A1 receptors preferentially bind acetylated LDL (Ac-LDL) in vitro. Macrophage-mediated uptake of 
modified LDL is achieved in part by SR-A1 [75]. Knockdown of the SR-A1 scavenger receptor in both LDLr-
/- and Apoe-/- led to a reduction in foam cell formation and atherosclerosis progression [76, 77]. Similar 
pro-atherogenic results observed in LDL-/- mice reconstituted with SR-A1-/- hematopoietic fetal liver cells 
demonstrates an important role for macrophage expression of SR-A1 with atherosclerosis [78]. Another 
scavenger receptor, CD 36, as a high affinity for oxidized LDL (ox-LDL) and has also been shown to bind 
minimally modified LDL species [79]. 
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(Hong et al., 2008, Curr Opin Gen Dev) 
Figure 4: Cholesterol homoeostasis in macrophages. 
Atherosclerosis is characterized by dysfunctional cholesterol metabolism of modified LDL. Receptor-
mediated lipid accumulation in macrophages is initiated by PRRs that bind to PAMPs/DAMPs. Cholesterol 
transport proteins ABCA1 and ABCG1 are down regulated in atherosclerosis, thereby preventing proper 
efferocytosis. Activation of LXR also dampens the expression of inflammatory genes. Dysfunction in the 
cellular processes eventually leads to foam cell formation and cell death. 
 
A member of the pattern-recognition receptor family (PRR), toll-like receptors (TLRs) also 
participate in macrophage-mediated lipid uptake. During an innate immune response, TLRs recognize 
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molecular patterns related to pathogenicity and/ or cell damage. Pathogen-associated molecular patterns 
(PAMPs) and damage-associated molecular patterns (DAMPs) typically derive from exogenous stimuli like 
lipopolysaccharide (LPS) and peptidoglycans. However, ox-LDL, ECM fragments, and HMGB1 are examples 
of endogenous PAMPs and DAMPs which activate signal transduction pathways that mediate atherogenic 
inflammation and plaque progression [81, 82]. 
Receptor-mediated lipid accumulation in macrophages and subsequent foam cell formation is a 
characteristic feature of atherosclerosis. At the same time, other mechanisms that govern the release of 
excess cholesterol and its transport by extracellular acceptors counteract atherogenic lipid uptake. ATP 
binding cassette A1 (ABCA1) is an intracellular transport protein found in macrophages that is upregulated 
by lipid loading. ABCA1 activity results in efflux of unesterified, free cholesterol (FC) and phospholipids 
(PL) to lipid-poor and/or lipid-free apoA-1 which is the major protein component of HDL [83, 84]. FC and 
PL efflux occurs simultaneously through an additional pathway that relies on ATP-binding cassette G1 
(ABCG1). ABCG1 releases FC and PL to mature HDL as a lipid acceptor but not to lipid-poor or lipid free 
apoA-1. The compensatory action of ABCA1 and ABCG1 have been attributed to the varied effects 
observed while studying either single knockout [85]. However, research has demonstrated that bone 
marrow (BM) generated from ABCA1/ABCG1 double knockout mice transplanted into LDL receptor 
knockout (LDLr-/-) mice exhibited accelerated atherosclerosis when fed a high-fat diet [86]. Further, [87] 
macrophage specific ABCA1-/- and ABCG1-/- (MAC-ABCDKO) BM transplanted into LDL-/- hosts not only had 
disproportionate atherosclerosis compared to wild type controls, but lesional macrophages displayed 
enhanced inflammatory gene expression as well. 
1.4.3 Therapeutics: 
Monocytes/macrophages are present in all stages of atherosclerosis and are the determinate cells 
throughout the atherosclerotic inflammatory response and plaque development. As such, therapeutic 
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interventions targeting monocyte/macrophage-related processes is imperative in prevention, cessation, 
and regression of atherosclerotic pathophysiology. 
Monocyte/macrophage recruitment and infiltration of the vascular endothelium are the initial 
steps in early lesion formation. Vascular adhesion molecule-1 (VCAM-1) plays an important part in this 
process through endothelium-leukocyte interactions. Antibody-derived VCAM-1 inhibition prevented 
leukocyte adhesion and transmigration in vitro, and reduced atherosclerosis in Apoe-/- mouse models [87]. 
Activated macrophages within the atherosclerotic plaque express interleukin-1 (IL-1) as 2 distinct isoforms 
IL-1α and IL-1β. While IL-1α generally remains associated with the cell surface, IL-1β has effector functions 
in several different cell types including: increased proliferation and MMP release by smooth muscle cells, 
degradation of vascular endothelial cells, and increased expression of MMPs and other proteolytic 
enzymes by macrophages [88]. Canakinumab is a monoclonal anti-human IL-1β antibody which is 
currently being evaluated in the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). 
Evaluation of Canakinumab efficacy in human patients revealed a dose -dependent reduction of greater 
than 50% for IL-6 and C-reactive protein [89, 90]. Several reports have indicated that IL-6 accelerates 
atherosclerosis. Under atherosclerotic conditions, activated macrophages produce IL-6 which stimulates 
expression of CRP, contributes to further macrophage activation, and exerts chemotactic effects that 
result in increased recruitment and accumulation of leukocytes [91, 92]. It has also been demonstrated 
that IL-6 administered to Apoe-/- mice via injection enhanced atherosclerosis progression [93]. 
In recent years, the use of micro RNAs (miRNA) as a therapeutic agent has provided a novel 
intervention for a myriad of diseases and disorders. miRNAs are short sequences of non-coding RNA, 
located within the introns or intergenic regions of protein coding genes. Co-transcription of miRNAs and 
their host genes is a function of their genomic proximity. Initially transcribed as pre-miRNAs, they are 
processed by enzymatic proteins (i.e. DROSHA, PASHA, DICER) which convert them into their bioactive 
form that is capable of binding to target mRNA sequences via the RNA-induced silencing complex (RISC) 
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[94-96].  MicroRNA-155 (MiR-155) is upregulated in the serum of atherosclerotic patients and in PMA-
stimulated THP-1 cells treated with ox-LDL. Moreover, transfection of THP-1 macrophages with a 
synthesized miR-155 mimic or inhibitor was performed to explore the effect of miR-155 overexpression 
and knockdown respectively [97]. Following treatment with ox-LDL, macrophage overexpression of miR-
155 resulted in attenuated lipid uptake, suppression of foam cell formation, and decreased TNF-α 
expression. Inhibition of miR-155 led to inverse effects on lipid uptake, foam cell formation, and TNF-α 
expression. 
Therapeutic intervention aimed at macrophage function remains a vast opportunity for novel 
approaches to disease prevention, cessation, and regression. New techniques that are unprecedented in 
their sophistication and elegance have given researchers the tools to search for a more expansive 
understanding of disease states and macrophage-related pathogenesis. 
1.5 Chitotriosidase 
Chitin is among the most abundant biopolymers in nature, second only to cellulose. It is a linear 
polysaccharide made up of repeating N-acetyl-D-glucosamine (GlcNAC) monomers. Chitin functions as the 
primary structural component in the exoskeleton of arthropods, and is produced by mollusks, 























                                                                                                           (Bueter et al., 2013, PLOS) 
Figure 5: Chitin in nature. 
Chitin is a linear biopolymer made up of repeating N-acetyl-D-glucosamine (GlcNAC) moieties. Structurally 
resilient, chitin can be found in the cell walls of fungi and parasitic helminths, it is also the main constituent 
of arthropod exoskeletons. Chitin itself is a dynamic regulator of inflammation in that chitin recognition 
by TLRs elicits various inflammatory cell functions. 
 
Endogenous chitin is not present in vertebrates and is, in fact, recognized by macrophage TLRs as 
a PAMP. Activation of the TLR signaling pathway elicits an innate immune response. Macrophage 
activation by chitin is characterized by release of inflammatory cytokines and chemokines. Chitinases are 
enzymes that degrade chitin into fragments small enough for phagocytosis as a host defense against 
chitin-containing pathogens [100]. Humans express two distinctly different chitinases: acidic mammalian 
chitinase (AMCase) and macrophage chitotriosidase-1 (CHIT1). AMCase is found largely in the stomach 
and lungs, and is most enzymatically active at pH 2.0. It is especially prevalent in bronchial asthma and 
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allergic airway inflammation [101, 102]. CHIT1 is highly expressed in activated macrophages. Named for 



















(Fusetti et al., 2002, Journal of biological chemistry and Fadel et al., 2016, PLOS)   
Figure 6: X-ray crystal structure of CHIT1 isoforms. 
(A) Stereo images of the Crystal structure of the 39 kDa CHIT1 isoform. It is a result of post-translational 
modification from the full-length enzyme. The truncated isoform still retains full enzymatic activity and is 
sequestered in specialized vesicles within the cell. (B) The full-length, 50 kDa isoform of CHIT1 includes the 
CBD (ChBD, chitin/carbohydrate binding domain) which potentiates enzymatic processivity. The hinge 
region that connects the enzyme to the CBD allows for multiple directionality of both subunits. 
 
Like most mammalian chitinases, CHIT1 is a member of the glycosyl-hydrolase enzymatic family 
18 (GH18). Cleavage of substrate is achieved through hydrolysis of β(14) glycosidic bonds. There are 2 
major isoforms of CHIT1 that arise from post-translational modification. In macrophages, CHIT1 is initially 
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synthesized as a 50 kDa protein. This isoform is either secreted in response to an inflammatory stimulus 
or packaged in lysosomes and lysosome related organelles (LRO) where the acidic environment within is 
believed to promote cleavage into a, still fully enzymatically active, 39 kDa isoform [105, 106]. A third 
isoform exists as a rare splice variant due to a point mutation that results in a 40 kDa protein that is 
essentially identical to the 39 kDa isoform. Recent discoveries have revealed that the difference in size 
between the 50 kDa and 39 kDa isoform is due to the presence of a carbohydrate-binding domain (CBM) 
[107, 108]. The CBM allows for processivity, which increases efficiency of hydrolysis by maintaining a close 
proximity between the enzyme and substrate during subsequent hydrolytic reactions. It should be noted 
that while CHIT1 expression has been observed in neutrophils very little is known about its mode of action. 
Data has provided evidence that CHIT1 is present in specialized vesicles that are unique from lysosomes. 
However, a mechanism to describe neutrophil-derived CHIT1 function has yet to be elucidated [109]. 
1.5.1 CHIT1 in disease 
A growing body of evidence describes the relevance of CHIT1 in a wide array of pathophysiologic 
conditions. Aside from acting as an effective defense mechanism against fungal infection or parasitic 
invasion, CHIT1 expression and secretion is unexpectedly increased in non-pathogen related, human 
diseases. Lysosomal storage disorders like Gaucher’s disease and Niemann-Pick disease are characterized 
by an extreme preponderance of lipid-laden, macrophage-derived foam cells. And while Gaucher’s 
patients present liver and spleen enlargement, patients afflicted with Niemann-Pick disease also display 
neurological abnormalities (i.e. cognitive decline, progressive ataxia, and seizures) [110, 111]. In both 
diseases, lipid-laden macrophages exhibit a steep rise in CHIT1 expression and secretion. 
Wound healing and tissue repair are natural physiological responses to injury. However, 
augmentation of these mechanisms can result in pathologic fibrosis. This is the case in chronic 
inflammatory conditions where persistent injury causes extracellular matrix (ECM) components to 
accumulate in excessive amounts. A role for CHIT1 in fibrosis is an intriguing assertion and this pathology 
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has been investigated in a number of pathologic conditions. Systemic sclerosis (SSc) is a disease that 
affects multiple systems and is characterized by cutaneous and visceral sclerosis. Pulmonary involvement 
is observed in approximately 70% of patients with SSc, and in many cases is manifested as interstitial lung 
disease (SSc-ILD) where normal lung tissue is replaced with inflamed fibrotic tissue [112]. In one study, 
the authors found that fibrosis was significantly diminished in CHIT1-/- following bleomycin-induced 
pulmonary fibrosis [113]. Also, they demonstrated that pulmonary fibrosis was significantly enhanced in 
transgenic mouse models that overexpress CHIT1. This effect was not bleomycin-specific, as a similar 
decrease in fibrosis was observed in transgenic CHIT1-/- mice that overexpress IL-13. IL-13 is capable of 
eliciting CHIT1 expression, and the cytokine is involved in Th2-mediated inflammation and fibrogenesis. 
The authors go on to describe that human fibroblast MRC5 cells incubated with recombinant CHIT1 and 
TGF-β showed enhanced expression of TGFR1 and diminished TGFR2 suppression which ultimately led to 
an increase in SMAD signaling.  
In cases of non-alcoholic steatohepatitis (NASH), TGF-β signaling is upregulated leading to 
steatosis, inflammation, and fibrosis. Research exploring a potential role of CHIT1 in NASH has provided 
evidence that CHIT1 was highly expressed exclusively by Kupffer cells in subjects with NASH [114]. CHIT1 
expression levels were significantly higher in patients, and this correlated with TNF-α release from 
hepatocytes and Kupffer cells, α-smooth muscle actin (α-SMA) from hepatic stellate cells, and pathogenic 
fibrosis. Additional studies will be required to determine whether CHIT1-mediated TGF-β signaling is 
involved in fibrogenic liver disorders. Research investigating the effects of CHIT1 on immune cells in 
neuromyelitis optica and multiple sclerosis revealed that monocytes isolated from patients with either 
disease expressed enhanced levels of MCP-1, RANTES, and IL-8 upon stimulation with CHIT1. Increased 
migratory capacity for macrophages was also observed in vitro [115].  
A number of different sources described elevated serum CHIT1 activity in atherosclerotic patients 
and animals [116-118]. Previously published data from our group has shown that CHIT1 inhibition using a 
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chitinase inhibitor, allosamidin, promotes atherosclerosis in ApoE-/- mice [119]. We observed significant 
alterations in macrophage cholesterol efflux and secretion of inflammatory cytokines and chemokines. 
RAW 264.7 macrophages were treated with allosamidin or medium alone. Transcripts for ABCA1, ABCG1, 
CD36, SR-A1, PPARγ, and LXRα were all significantly down regulated upon allosamidin treatment. Similar 
results were achieved in bone marrow-derived macrophages (BMDM). Pro-inflammatory cytokines and 
chemokines associated with M1 macrophage polarization: MCP-1, TNF-α, iNOS, IL-6, IL-12, IL-1β were 
significantly upregulated in both cell types when treated with allosamidin and IFN-γ compared to those 
treated with IFN-γ alone. Both lipid uptake and cholesterol efflux were decreased in RAW 264.7 
macrophages when treated with allosamidin. Perhaps most intriguing was data that indicated promotion 
of atherosclerosis in ApoE-/- mice fed a Western diet and administered allosamidin compared to vehicle 
control via surgically implanted pump. After 6 weeks on high-fat diet, histological analysis depicted a 
significantly larger lesion in the aortic arch of animals with CHIT1 inhibition. Moreover, we found that 
lesion area was also significantly larger in the aortic sinus, and that macrophage deposition was also 
significantly greater. 
1.6 Hypothesis and Aims: 
Inflammation and dysfunctional cholesterol metabolism are fundamental components in the 
pathogenesis of atherosclerosis. CHIT1 is a highly-expressed protein in activated macrophages. It’s 
production and secretion are elicited during both M1 and M2 inflammatory responses. Furthermore, 
Chitinase inhibition has been shown to stimulate pro-inflammatory cellular functions, decreased 
transcription of lipid-handling genes in vitro, and promoted atherosclerosis in hyperlipidemic mice. In light 
of these findings we tested the hypothesis that CHIT1 overexpression has athero-protective qualities that 




Aim 1) Investigate the effect of CHIT1 over-expression on the inflammatory response and 
invasiveness by macrophages 
Aim 2) Determine whether over-expression of CHIT1 modulates cholesterol uptake and efflux 
in macrophages 






















CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Mouse strains 
Wild-type C57BL/6 mice and LDLR null mice generated on a C57BL/6 background animal were 
purchased from Jackson Laboratories (Bar Harbor, Maine). CHIT1-OE mice were developed in cooperation 
with Kyushu University and Riken research Institute (Saitama, Japan). Briefly, the transgene depicted in 
figure 7 was microinjected into fertilized mouse embryos. To confirm transgene expression, gel 
electrophoresis was used to detect the presence of primer sequences specific to the CHIT1 transgene. 
Ldlr-/-were crossbred with CHIT1-OE mice to produce Ldlr-/--CHIT1-OE animals. Mice between 8-12 weeks 
of age were used for isolation of bone marrow derived macrophages. Male Ldlr-/--CHIT1-OE mice between 
8-10 weeks were utilized for the in vivo atherosclerosis study. All animal studies and protocols were 
approved by the University of Hawaii Institutional Animal Care and Use Committee. 
2.2 Bone marrow-derived macrophage cell isolation and in vitro cell culture: 
Experimental and control mice were sacrificed by CO2 asphyxiation at 8-10 weeks of age. 70% 
EtOH was sprayed on the animals to disinfect the skin. Each femur and tibia were surgically removed under 
a biosafety hood. Using a 30-gauge needle, the marrow within the exposed bones were flushed out with 
ice cold PBS into a 50-mL falcon tube while on ice. The isolated bone marrow was broken up by vigorous 
pipetting with a 10-mL pipette. It was then passed through a 40-µm cell strainer into a 50-mL falcon tube, 
and centrifuged at 1300 RPM (≈300 x g) for 5 minutes to form a pellet. PBS was aspirated and the 
remaining pellet was resuspended in BMDM differentiation medium (DMEM/F12, [Gibco, Dublin, Ireland], 
10% FBS, 20% L929 conditioned medium, and 1% penicillin-streptomycin (pen/strep) [Gibco, Dublin, 
Ireland]). Cell viability was determined by staining a 10 µL sample of cells in suspension with trypan blue. 
Cells were cultured at a density of 1×106 cells per mL and plated in 15-cm tissue-culture treated plates 
(Corning, Tewsbury, Massachusetts) with 25 mL of medium. 5-10 mL of media was added to the plate 
every other day for 7 days. Differentiated macrophages adherent to the plate were detached using non-
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enzymatic Cell Stripper solution (Gibco, Dublin, Ireland). The cells were then counted and re-plated as 
specified in each experiment. 
2.3 Preparation of L929-conditioned media: 
L929-conditioned media was prepared by culturing 4.7×105 L929 cells (ATCC, Manassas, Virginia) 
in T-75 flasks containing 50-mL of media (DMEM/F12, 10% FBS, 1% HEPES (Gibco, Dublin, Ireland), and 1% 
pen/strep) for 7 days before collecting and sterile filtering the supernatant. The conditioned media was 
kept in 50-mL aliquots at -80° C for long-term storage and 20° C for short-term storage. 
2.4 Western blot 
2.4.1 Preparation of lysates from cells and tissues 
RIPA buffer (10 mM Tris-Cl [pH 7.6], 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 
0.1% SDS, 140 mM NaCl) and 1X Halt protease and phosphatase inhibitor cocktails (Thermo Fisher, 
Waltham, Massachusetts) was used in preparation of lysates. Adherent cells in 6-well plates were washed 
with PBS which was then aspirated from each well before adding 100 µL of 4oC cold lysis buffer with 
protease/phosphatase inhibitor cocktails (diluted 1:1000) (Roche). Plates were kept on ice for 15 minutes 
before scraping the wells with a cell scraper and transferring the lysates to 1.5 Milliliter Eppendorf tubes 
on ice. Samples were then sonicated by pulsing 10 times with a probe sonicator (Thermo Fisher, Waltham, 
Massachusetts) at power level 2.5, and centrifuged at 400 x g for 5 minutes at 4° C. Lysates were 
transferred to a new Eppendorf tube and the pelleted cell debris was discarded. Pierce BCA protein assay 
kit (Thermo Fisher, Waltham, Massachusetts) was used to determine protein concentrations of lysates in 
a 1:10 dilution of samples. 
2.4.2 Polyacrylamide gel electrophoresis and Western blot transfer 
Precast NuPAGE® Novex® 4-12% Bis-Tris Mini or Midi protein gels (Invitrogen, Carlsbad, California) 
with 12 or 20-lanes respectively, were used in conjunction with the appropriate mini or midi 
electrophoresis gel box. 4x SDS loading buffer (0.1 M Tris-HCl pH 6.8, 0.7% SDS, 33% glycerol, 0.01% 
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bromophenol blue, 8% β-mercaptoethanol) was added to 10-20 µg of protein and this mixture was heated 
and maintained at 95° C for 5 minutes. Samples were loaded into each lane and 4 µL of Li-cor 1-color 
protein marker was added as a size reference latter. Gels were run in 1X NuPAGE® MES SDS Running Buffer 
(Invitrogen, Carlsbad, California) at a constant voltage of 150 V until the loading dye has completely 
migrated to the bottom of the gel. The gel is removed from its casing and placed on a low florescence 
PVDF membrane that has been activated in 100% methanol and immersed in 1x Efficient™ Western 
Transfer Buffer (G-Biosciences® #786-019 St. Louis, Missouri) with 20% methanol for 5 minutes. The gel 
and membrane together were placed between sheets of filter paper soaked in transfer buffer, and 
compressed tightly within the transfer cassette. The transfer cassette was placed in the transfer chamber 
along with an ice pack and stir Rod. The chamber was then put on ice. Protein was transferred to the 
membrane after running for 1 hour at 100 V. 
2.4.3 Membrane incubation with antibodies and scanning 
The membranes were blocked in 1:1 Li-cor blocking buffer and PBS for one hour with gentle 
agitation on an orbital shaker. The blocked membranes were incubated with primary antibodies diluted 
in Li-cor blocking buffer at room temperature for one hour or at 4° C overnight. Membranes were 
subsequently washed 3 times with 0.1% Tween20 in PBS. Secondary antibodies diluted in Li-cor blocking 
buffer were incubated with membranes at room temperature for one hour in the dark. After washing 3 
times for 5 minutes each with 0.1% PBST, membranes were scanned with a Li-cor Odyssey infrared 




Table 1: List of antibodies used for Western blotting 
 
Name Species Company Dilution 
CHIT1 Goat α Mouse Santa Cruz 
Biotechnology 
1:500 
β-actin Rabbit α Mouse Sigma 1:2000 
MAPK (ERK1/2) Mouse α MAPK Cell Signaling 1:1000 
pMAPK ser (pERK1/2) Rabbit α Mouse Cell Signaling 1:1000 
pAKT  ser Rabbit α Mouse Cell Signaling 1:1000 
PIκB-α Rabbit α Mouse Cell Signaling 1:1000 
IRDye 800CW Donkey α Rabbit Licor 1:10,000 
IRDye 800CW Donkey α Goat Licor 1:10,000 
IRDye 680CW Donkey α Mouse Licor 1:10,000 
 
 
2.5 Reverse transcriptase quantitative PCR (RT-qPCR) 
Total RNA was extracted by adding 500 µL-1 mL TRIzol reagent (Life Technologies, Carlsbad, 
California) to each sample in a 1.5 mL Eppendorf tube. The sample was then vortexed until completely 
dissolved and chloroform was added to TRIzol in a 20% v/v ratio, and inverted vigorously to mix. The 
samples were centrifuged at 12,400 RPM for 15 minutes in a pre-cooled centrifuge at 4° C. Once phase 
separation occurs, the aqueous fraction was carefully pipetted into a separate tube and combined with 
an equal volume of nuclease-free, 70% ethanol. Samples were mixed thoroughly and put through RNA 
purification columns provided in the Qiagen RNeasy RNA extraction kit. DNA digest was performed, on-
column, for 15 minutes at room temperature. After the appropriate wash steps, columns were allowed to 
completely dry. Elution of RNA from the columns was performed using 30-50 µL nuclease-free water. RNA 
concentration and quality was determined with a NanoDrop 2000. RNA was used immediately for RT-
qPCR or stored at -80° C. 1 µg of total RNA per sample would be used to transcribe cDNA using the qScript 
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cDNA synthesis kit (Quanta Biosciences, Beverly, Massachusetts). 80 µL of nuclease-free water was added 
to each cDNA sample, bringing the total volume to 100 µL. In performing the RT-qPCR, 4 µL of cDNA was 
added to each well along with a master mix of 12.5 µL SYBR Green 2X master mix containing ROX (Roche), 
0.5 µL of both forward and reverse primers (10 µM), and 7 µL of nuclease-free water. Ten µL of the 
reaction mixture was pipetted in triplicate to a 384-well qPCR plate and analyzed with an Applied 
Biosystems 7900HT Fast Real-Time PCR System. 
Table 2: List of qPCR primers 
Gene Forward sequence (5’-3’) Reverse sequence (3’-5’) 
Gapdh GGC AAA TTC AAC GGC ACA GT CGC TCC TGG AAG ATG GTG AT 
CHIT1 GAT GTG GAT CCC AAC CTG TGT ACC GGG TCT TGA GCT TGG GGT TCT TAG 
ABCA1 CCC AGA GCA AAA AGC GAC TC GGT CAT CAT CAC TTT GGT CCT TG 
ABCG1 CAA GAC CCT TTT GAA AGG GAT CTC GCC AGA ATA TTC ATG AGT GTG GAC 
CD36 CAA GCT CCT TGG CAT GGT AGA TGG ATT TGC AAG CAC AAT ATG AA 
IL-1β TCC AGG ATG AGG ACA TGA GCA GAA CGT CAC ACA CCA GCA GGT TA 
IL-6 GAC AAC CAC GGC CTT CCC TA CTG CAA GTG CAT CAT CGT TGT TC 
iNOS TGC ATG GAC CAG TAT AAG GCA AGC GCT TCT GGT CGA TGT CAT GAG CAA 
LXRα CTC CTG ATT CTG CAA CGG AGT TGT G TCC AAC CCT ATC CCT AAA GCA ACC C 
PPARγ CGG AAGCCC TTT GGT GAC TTT ATG G GGG CGG TCT CCA CTG AGA ATA ATG A 
MCP-1 TCA CTG AAG CCA GCT CTC TCT GTG GGG CGT TAA CTG CAT 
TNF-α CCT CCA GAA AAG ACA CCA TGA G CAC CCC GAA GTT CAG TAG ACA G 





2.6.1 Immunoprecipitate preparation 
BMDM from wild type and CHIT1-OE mice were cultured for 6 hours with or without LPS + IFN-γ. 
The supernatant was then collected and 850 µL were transferred to microcentrifuge tubes. 2 µg of goat, 
anti-mCHIT1 primary antibody was added to the tube. The supernatant-antibody mixture was incubated 
for 1 hour at 4° C. Twenty µL of Protein G PLUS-Agarose beads (Santa Cruz Biotechnology, Dallas, Texas) 
were then added to the tubes and incubated at 4°C overnight. The immunoprecipitates were collected by 
centrifugation and washing with 20 mM Tris-HCl, pH 7.4. Protein elution is carried out by resuspending 
the pellet in glycine buffer and incubatinfg for 10 minutes at 4° C. The solution is centrifuged and the 
eluate is collected, it is then immediately neutralized by adding 1 molar Tris, pH 8.5. This step is repeated 
3 times and each resultant elution is analyzed with Western blot and SDS-PAGE. 
2.6.2 Coomassie Blue staining (total protein control) 
The same PVDF membranes used for immunoprecipitation were stained using Coomassie Brilliant 
Blue “G” (Sigma-Aldrich, St. Louis, Missouri). The Western blot membrane was washed for 5 minutes at 
room temperature and then stained with 65% Coomassie stained solution and incubated for 5 minutes at 
room temperature. The membrane was washed with 50% methanol, 10% acetic acid the staining solution. 
The membrane is visualized using the Li-cor CLx Odyssey imaging system at 700 nm. 
2.7 CHIT1 activity assay 
Chitinase activity in cell lysates was performed as described above, however in place of RIPA 
buffer, a non-denaturing lysis buffer was prepared in order to preserve enzymatic activity of CHIT1. The 
lysis buffer cocktail contained: 50 mM Tris-HCL, 200 mM NaCl, 10% glycerol, and for 0.5% Triton X-100. 
CHIT1 activity was detected using 4-methylumbelliferyl-N, N’, N”-triacetyl chitotrioside [4MU-(GlcNAc)3, 
Sigma-Aldrich] as a substrate. A 20 µM working solution of 4MU-(GlcNAc)3 was prepared by dissolving in 
N, N-dimethylformamide. This was added to 8 µg of protein sample prepared from cell lysates and allowed 
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to incubate for one hour at 37° C in 50 mM citric acid/NaPO4 incubation buffer. The reaction was stopped 
using 1M glycine/NaOH stop buffer. Florescence of liberated 4-Methylumbelliferone was measured with 
a fluorescence spectrometer (excitation: 360 nm, emission: 450 nm). A 4-MU standard solution curve was 
used to calculate absolute chitinase activity (U/mL) 
2.8 Cytokine array 
The Proteome Profiler Array: Mouse Chemokine Array Kit (R&D Systems, Minneapolis, Minnesota) 
was used to determine relative levels of 40 different mouse Cytokines and Chemokines. Cell lysates were 
prepared by rinsing BMDM cultures with PBS and then adding 100 to 150 µL of lysis buffer to each well. 
The cells and lysis buffer are incubated for 30 minutes before harvesting with a cell scraper. Protein 
concentration was determined using BCA assay. Two mL of array buffer 6 (blocking buffer) is added to 
each well and the pre-blotted, nitrocellulose membranes that were provided in the kit are added to the 
wells. The membranes were incubated for 1 hour at room temperature. Fifteen µL of reconstituted Mouse 
Cytokine Array Panel A Detection Antibody Cocktail was added to each sample containing 100 µg total 
protein. The wells were emptied of Array Buffer 6 and the samples/antibody mixtures were added to the 
wells and allowed to incubate overnight at 2-8° C on a rocking platform shaker. Each membrane was 
washed and then 2 mL of IRDye 800CW Streptavidin (LI-COR, Catalog #926-32230) diluted 1:2000 using 
the Array Buffer 6 was added to each well of the dish. After incubating for 30 minutes at room 
temperature, each membrane was removed and images were collected with an Odyssey CLx imaging 
system. 
2.9 Cholesterol homeostasis assays 
2.9.1 Cholesterol uptake using fluorescently labeled cholesterol 
Cholesterol uptake was measured in bone marrow-derived macrophages from CHIT1-OE mice and 
littermate controls. BMDM were plated at a density of 1×106 cells per well in 12-well plates for flow 
cytometry analysis. Cells were treated with 50 µg/mL DiI-labeled acetylated-LDL (Ac-LDL), BODIPY-labelled 
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Ac-LDL, DiI-labelled oxidized-LDL (ox-LDL), and BODIPY-labelled ox-LDL as separate treatments with or 
without 20 ng/mL IFN-γ + 100 ng/mL LPS. Experiments were carried out for 4, 6, 12, and 24 hours of 
incubation. The cells were then detached with cell stripper and fixed for 10 minutes with 4% PFA in 
preparation for flow cytometry analysis of fluorescence intensity corresponding with DiI- and BODIPY-
labelled lipids. The immunoprecipitates are collected by centrifugation and the pellet is resuspended with 
20 mM Tris-HCl, pH 7.4. Following the immunoprecipitation process the pellet is resuspended with 50 µL 
of glycine buffer and incubated for 10 minutes at 4° C. The sample solution is centrifuged and the eluate 
is immediately neutralized with one molar TRIS, pH 8.5. The elution step is repeated 3 times2.9.2  
2.9.2 Cholesterol efflux using [H]3-cholesterol 
BMDM from both CHIT1-OE mice and littermate controls were plated at a seeding density of 1×106 
cells per well in 24 well plates. Cells were incubated overnight to promote adhesion. After incubation cells 
are washed with PBS and then labeled with loading medium which containing: DMEM, glutamine, 
penicillin, streptomycin, 0.2% fatty acid-3 bovine serum albumin, AcLDL (50 μg/ml), and 1 μCi/μl [3H] 
cholesterol (NEN Life Science products Santa Clara, California), for 24 hours. The cells were washed twice 
with PBS and equilibrated for 2 hours in efflux media (DMEM and 0.2% BSA). Cells were washed again 
with PBS and then incubated in 0.5 mL efflux media alone or with either 20 µg/mL ApoA1 (indicates 
ABCA1-mediated efflux) or 50 µg/mL HDL (indicates ABCG1-mediated efflux) added to the well. The 
BMDM were incubated for 6 hours at which time the supernatant was collected and analyzed with a 
scintillation counter to determine the amount of radiolabeled cholesterol efflux by the macrophages via 
HDL or ApoA1. 
2.10 Macrophage invasion assay 
Cultured BMDM were washed once with PBS and 15 mL of 1% pen strep serum free media was 
added, and cells were incubated at 37° C for 3 hours to starve cells. Cells were washed once with PBS and 
detached by incubation with cell stripper for 5 to 10 minutes. Using a cell lifter, BMDM were collected 
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from the plate and spun down for 5 minutes at 1300 RPM in a falcon tube. ECM Matrigel (Sigma-Aldrich 
St. Louis, Missouri) was diluted 1:1 with DMEM to a 6 mg/mL working solution. Using chilled pipette tips, 
50 µL of matrigel was added to transwell inserts in 24 well plates. Each insert contained a membrane with 
0.8 µm pores through which the macrophages migrate after invasion of ECM. After matrigel has solidified 
for 10-30 minutes, 100 µL of cell suspension (1×105 BMDM) was pipetted onto the solidified matrigel layer. 
600 µL of either serum free media or experimental cell culture media alone and experimental cell culture 
media supplemented with MCP-1, reconstituted chitin from shrimp shells, or IL-13 was added to the well 
below the transwell inserts. Macrophages were incubated for 24 hours at 37° C and supplemented with 
5% CO2 to observe cellular invasion. In order to visualize macrophages that invaded ECM layer the inserts 
were removed and the top of each membrane was carefully swabbed with a cotton-tipped applicator to 
remove media and noninvasive cells. Transwell inserts were submerged in 70% alcohol for 10 minutes to 
fix cells. Membranes were subsequently stained with 0.2% crystal violet at room temperature. Each 
transwell insert was then carefully dipped into distilled water as to avoid washing off fixed cells while 
removing excess crystal violet stain. The insert with the membrane still attached was then viewed under 
an inverted microscope and stained sections were quantified using ImageJ software. 
2.11 Mouse atherosclerosis study 
2.11.1 Blood collection and sacrifice of study animals 
Blood from each mouse was collected at the start and end point of the study using a 
submandibular bleeding technique. A portion of the whole blood collected was centrifuged at 1500 x g 
for 15 minutes to achieve plasma separation. Plasma samples were used to measure lipid levels. At the 
study’s conclusion, animals were euthanized by CO2 asphyxiation and total blood was collected through 
cardiac puncture of the left ventricle. Liver, spleen, lymph nodes and kidneys were removed and each 
mouse was perfused with ice cold PBS followed by 4% PFA/5% sucrose. The hearts and your orders were 
removed and analyzed as described below. 
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2.11.2 Analysis of blood cell populations by flow cytometry 
Blood collected in EDTA tubes was agitated by gently tapping the tubes and then put on ice. 5 mL 
of red blood cell lysis buffer (eBioscience Santa Clara, California) was used was applied to whole blood for 
15 minutes at room temperature. 5 mL of PBS was then added to the tubes and centrifuged at 350 x g for 
5 minutes. A second treatment with RBC lysis buffer was performed if the cell pellet showed signs of RBC 
contamination. This was done by adding 1 mL of lysis buffer for an additional five minutes before adding 
PBS and centrifuging. To re-suspend the cell pellet, 200 µL of Hank’s complete buffer (recipe below) was 
added and then transferred to a round-bottom 96-well plate and centrifuged. The remaining supernatant 
was decanted by inverting the plate. An antibody master mix was prepared with 0.5 µL of each required 
antibody and brought to a total volume of 50 µL using 50% flow blocking buffer (recipe below) and 50% 
Hank’s complete buffer per sample. The cell pellet was resuspended in 50 µL of the antibody master mix 
and incubated for 20 minutes on ice, in the dark. 150 µL of Hank’s complete buffer was used to wash the 
cells which were then centrifuged. 
Table 3: The list of flow cytometry antibodies 
 
Antigen Fluorophore Company Dilution 
Ly6G PE Biolegend 1:100 
Gr-1 APC Invitrogen 1:800 
CD45 APC-Cy7 Biolegend 1:100 
CD11b PerCP-Cy5.5 Biolegend 1:100 
CD11c PE-Cy7 Biolegend 1:100 
CD3 AlexaFluor700 Biolegend 1:100 
CD4 PE-Texas Red Biolegend 1:100 
CD8 eFluor450 eBioscience 1:100 




2.11.3 Analysis of serum cholesterol and triglyceride levels 
At the end of the atherosclerosis study blood cholesterol and triglyceride measurements were 
gathered from serum samples of all mice in each group. A fluorometric assay kit (Cayman Chemical) was 
used to determine total cholesterol. Samples were diluted 1:200 with assay buffer in duplicates prepared 
in a 96-well plate. Serum samples were also analyzed for triglyceride levels. A colorimetric assay (Cayman 
Chemical Ann Arbor, Michigan) allowed for the measurement of fluorescence or absorbance using a 
SpectraMax Microplate Reader. Standard curves were derived from standard solutions provided in the 
kit. 
2.11.4 Analysis of lesion area of whole aortas and aortic root cryosections 
Upon dissection of the animal, adventitial fat was cleared away from aorta and branching arteries. 
The entire aorta was then cut open longitudinally, excised, and pinned to a wax lined dissecting tray. Oil-
Red-O Stock (ORO) solution was prepared with 1 gram of ORO powder (Sigma-Aldrich St. Louis, Missouri) 
dissolved in 300 mL of 99% isopropanol. A working solution of the stain was prepared fresh by mixing 180 
mL of stock solution with 120 mL Milipore water. The solution was allowed to equilibrate for one hour 
before filtration with Whatman filter paper into a clean glass bottle. 60% isopropanol was used to wash 
the pinned aortas which were then completely submerged in ORO working solution for 15 minutes. The 
aortas were washed with 60% isopropanol until the stain was no longer visibly being removed (3-4 
washes). Aortas were photographed and the images were analyzed to measure plaque area using the 
ImageJ software. 
Fixed hearts were collected from the study mice and mounted in Optimal Cutting Temperature 
(OCT) compound (Tissue-Tek Torrance, California) which were then frozen at -80° C. Embedded hearts 
were sectioned in a sagittal orientation through the aortic valve were all 3 leaflets are visible. Cryo-
sectioning was achieved with a cryostat and serial sections of 10 µm increments were made, and 5 
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representative sections were selected from each mouse. These sections would be used to visualize lesion 
area as represented with ORO staining. Newly prepared cross-sections were incubated in PBS for 5 
minutes and then air dried. They were dipped 10 times in 60% isopropanol and then stained with fresh 
ORO working solution for 15 minutes. The staining solution was removed and the slides were again dipped 
10 times in isopropanol and washed for 5 minutes under running tap water. Slides were covered using 
mounting media (Sigma-Aldrich) and dried overnight. Photos were taken of the sections at 5X zoom and 
the ORO stained area was quantified using ImageJ and represented as a percentage of total aortic area. 
Table 4: List of antibodies used for immunohistochemistry staining 
Antigen Company Dilution 
Rat α MOMA Abcam 1:1000 
Goat α CHIT1 Santa Cruz Biotechnology 1:500 
 
2.11.5 Immunohistochemical staining of aortic root cryosections 
Immunohistochemical (IHC) staining was used to characterize and quantify CHIT1 expression, 
macrophage populations, necrotic core area, ECM deposition, and collagen formation in WT and CHIT1-
OE mouse, aortic cryosections. Slides with mounted cryosections were prepared for IHC by fixing in ice 
cold, 100% acetone for 1 minute and then washed with PBS using dip-style glass chamber. Tissue sections 
were circled with a PAP pen and then washed with PBS-Tween. Antigen retrieval was carried out using 
0.05% trypsin/0.1% calcium chloride solution (trypsin/CA). Slides were incubated with trypsin CA in a 
humidified chamber at 37° C for 15 minutes, and allowed to cool at room temperature for 10 minutes. 
Antigen retrieval solution was removed and slides were washed 3 times with PBS-Tween. 0.1% Triton X-
100 was then applied for 20 minutes, removed, and slides were washed again with PBS-Tween. 
Hydrogen peroxide block was performed by adding enough 3% hydrogen peroxide to cover each 
section and incubate until bubbles can no longer be observed emanating from the tissue. Slides were then 
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rinsed with PBS and placed in a dip chamber containing PBS for 2 minutes. Sections were blocked with 5% 
donkey serum dissolved in 2% BSA with 1X PBS. Slides were incubated in block solution for 1 hour at room 
temperature.  
Primary antibodies for CHIT1 (Santa Cruz Biotechnology Dallas, Texas) and macrophages (MOMA-
2, Abcam Cambridge, United Kingdom) were added to the sections and allowed to incubate overnight at 
4° C. Sections were washed with PBS-Tween followed by addition of the horseradish peroxidase (HRP), 
conjugated secondary antibody. Slides were incubated in a dark humidified chamber for 1 hour at room 
temperature. Sections were washed with PBS-Tween and kept wet until mounted. One drop of reagent a 
was diluted in 1 mL of distilled water as described in the AEC staining kit instructions (Invitrogen, Carlsbad, 
California). One drop of reagent be and reagent C were then added and the solution was kept away from 
light and incubated with the cryosections for 30 minutes (or until color development is satisfactory). Slides 
were then rinsed with distilled water. Mayer’s hematoxylin counter stain was applied using a dip chamber 
for no more than 10 seconds. The slide was then washed and rinsed under running tap water for 5 
minutes. Next, the slides were put into a dip chamber containing Scott’s Bluing solution for 30 seconds 
and dipped once in tap water to wash. Dako fluorescent mounting media was added to the top of each 
section, which was then covered with a coverslip and stored at 4° C. 
Visualization of hyaluronic acid was achieved using biotinylated hyaluronic acid binding protein 
(BHABP, EMD/Millipore/Calbiochem Burlington, Massachusetts). After acetone fix, hydrogen peroxide 
block, and blocking (2% BSA in 1X PBS), streptavidin/biotin blocking was performed according to the 
instructions provided by the kit (Vector Laboratories Burlingame, California): incubate section with Avadin 
D solution for 15 minutes at room temperature rinse with PBS-Tween, next incubate section with biotin 
solution for 15 minutes at room temperature and rinse again with PBS-Tween. BHABP was diluted 1:100 
in blocking solution and applied to sections. These were allowed to incubate at room temperature for one 
hour. BHABP was aspirated away and slides were washed 3X with PBS. The streptavidin-conjugated HRP 
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was then applied to the cells for 1 hour at room temperature before washing 3X with PBS. AEC chromogen 
and Mayer’s hematoxylin counter stain was added as described above. 
Hyaluronidase negative controls sections were prepared in the same way as sample sections. 
However, no detection stain was added. Instead, cryosections were incubated with hyaluronidase 
(StemCell Technologies Vancouver, Canada) for 2 hours at room temperature. 
Picro-Sirius Red staining was used to visualize collagen in the aortic root. Cryosections were 
acetone fixed and trypsin/CA antigen retrieval was applied. As described in the instruction manual (Abcam 
Cambridge, United Kingdom), Picro-Sirius red solution was added to completely cover the section, and 
incubated for 60 minutes. The slide was rinsed with 2 changes of acetic acid solution, and then rinsed 
once in absolute alcohol. The cryosections were then dehydrated into changes of absolute alcohol and 
the slide was mounted in resinous mounting media. 
2.12 Statistical analyses 
 A minimum of 3 biological replicates run in duplicate or triplicate were analyzed for in vitro 
experiments as indicated. Statistical power of 0.8 was utilized for determination of significance and 
sample size, such that variation as represented by  standard deviation within groups  did not exceed an 
acceptable threshold  for sample size n=3. For qPCR analysis, transcript abundance was determined from 
cDNA isolated from samples. CT values were initially normalized to GADPH and expressed as the average 
fold change relative to controls for each treatment. Error bars represent the SEM. These cytokine array 
used protein samples from 3 biological replicates and was performed in duplicate for each treatment. 
Values are representative of an average of the duplicate measurements ± SEM. 
 Using flow cytometry we determined cholesterol uptake in vitro. The intensity of DiI 
florescence/cell was ascertained with 10,000 counts for each sample in duplicate. Mean fluorescence 
intensity (MFI) of DiI was measured in 3 biological replicates and depicted as an average MFI of CHIT1-OE 
cells compared to controls ± SEM. Cholesterol efflux measurements taken in vitro were performed in 
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triplicate from 3 separate experiments. Basal cholesterol efflux level (no acceptor), efflux to ApoA1, or 
HDL is shown as a percentage of the total cholesterol loaded by cells. Bar graphs represent the average 
values derived from experiments ± SEM. 
 Invasion assay was performed 3 times in duplicate. For imaging, a total of 5 photos were taken 
from each insert and analyzed with ImageJ. Macrophage invasion is represented by the average of stained 
areas from all 5 photos as a percentage of the total area captured in each photo. Statistical analysis with 
prism for all in vitro experiments was carried out using the two-tailed Welches t-test with p<0.05 as 
threshold for significance. 
 The in vivo mouse study compared 2 groups with 14 mice in each group therefore resulting in a 
df of 26, a student T value of 2.06, and a significance value α=0.05 (two-tailed). A minimum of 6 mice per 
group was used to determine statistical significance. P values for all experiments were calculated with the 





CHAPTER 3: RESULTS 
 
3.1 Verification of CHIT1 overexpression in macrophages 
Initial experiments were performed in order to observe CHIT1 overexpression in BMDM harvested 
from CHIT1-OE mice. As mentioned above, CHIT1-OE mice were crossbred with ldlr-/- mice, thereby 
providing us with a atherosclerotic, CHIT1 overexpressing mouse model. Moreover, CHIT1 overexpression 
is achieved using the Cre-Lox system whereby the removal of a LoxP-flanked stop sequence allows for 
conditional overexpression of CHIT1 in lysozyme producing macrophages. Conditional overexpression 
with LysMCre is made possible because the Cre recombinase gene is inserted after the promoter of the 
LysM gene and as lysozyme is constitutively expressed so too is Cre recombinase, and with that CHIT1. 
Thus, the genetic description of our experimental mouse models can be described as follows: ldlr-/-- CHIT1-
OE-LysMCre. 
Figure 7: CHIT1 overexpression transgene design 
(A) The transgene was designed with an EGFP stop sequence (green) that is removed in the presence of 
Cre recombinase. When Cre recombinase is expressed in lysozyme producing cells, the CHIT1 gene (blue) 
is constitutively expressed by macrophages. (B) Results from genotyping F0 mice indicate the presence of 











Figure 8: CHIT1 overexpression in vitro 
(A) Transcription of CHIT1 mRNA was quantified using qPCR. cDNA was isolated from control and CHIT1-
OE BMDM. (B) CHIT1 activity was analyzed in BMDM from control (Cre-) and CHIT1-OE (Cre+). Liberated 
4-MU emission was measured with a plate reader to determine enzymatic activity. (C) Western blot 
imaging of CHIT1 protein expression. Both isoforms (50 kDa and 39 kDa) were significantly increased in 
BMDM from CHIT1-OE mice compared to controls. (D) Membranes after Western blot were imaged using 
Licor Odyssey CLx and analyzed with image studio software measurements reflect the fold change in 
florescence intensity. (E) immunoprecipitation was performed on supernatants of BMDM harvested from 
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control. (F) Analysis of Western blot images with image studio software showed a significant increase in 
CHIT1 protein expression. N=3 *P<0.05 **P<0.01 
To verify the overexpression of CHIT1 in macrophages, BMDM were harvested from both 
experimental and littermate control animals. Isolated RNA was analyzed with “quantitative” PCR (qPCR). 
We found that CHIT1 transcription was not affected in control BMDM as the transcript detected was 
similar to our internal control, GADPH (figure 8A). CHIT1 transcription was significantly increased in CHIT1-
OE BMDM when compared to control BMDM. Cell lysates were prepared from BMDM and visualized using 
Western blot analysis. Figures 8C and 8D show protein expression was enhanced in CHIT1-OE BMDM as 
evidenced by the presence of one distinct band at 50 kDa and one at 39 kDa, which are characteristic of 
the predicted molecular weight of both CHIT1 isoforms. The 39 kDa isoform of CHIT1 is a product of the 
post-translational modification of the 50 kDa isoform, and was only visible in CHIT1-OE BMDM. Due to the 
fact that only the 50 kDa isoform of CHIT1 is secreted while the 39 kDa isoform is sequestered in 
specialized vesicles, analyzed the supernatant of macrophage cell cultures for the presence of CHIT1. As 
expected, we found that the 50 kDa, secreted isoform of CHIT1 was robustly expressed in the supernatant 
of CHIT1-OE BMDM (figure 8E and 8F). Lastly, we determined that CHIT1 enzymatic activity is elevated in 
both cell lysates and the supernatant of CHIT1-OE BMDM as exhibited by the cleavage of 4-MU-
conjugated substrates. 
3.2 effects of CHIT1 overexpression on macrophage function 
3.2.1 Overexpression of CHIT1 modulates inflammatory responses in macrophages 
We examined the effects of CHIT1 overexpression on macrophage inflammatory response by 
treating BMDM from CHIT1-OE mice with a combination of IFN-γ and LPS. Incubation of cells for 6 hours, 
followed by RNA isolation, and qPCR analysis revealed exaggerated transcription levels of CHIT1 as well 
as suppressed transcription of inflammatory cytokines compared to BMDM from littermate control 





Figure 9: Macrophage overexpression of CHIT1 reduces pro-inflammatory gene expression 
BMDM from CHIT1-OE (CRE+) and control mice (CRE-) were treated with 20 ng/mL IFN-γ + 100 ng/mL LPS 
for 6 hours or left untreated as experimental control. Cellular RNA was extracted to prepare cDNA for qPCR 
analysis. Gapdh, a well-known housekeeping gene was used as internal control. (A) CHIT1 gene expression 
was strongly enhanced in CHIT1-OE mice when subjected to inflammatory stimuli. (B-D) Treatment with 
IFN-γ + LPS for 6 hours resulted in a marked decrease in transcription of pro-inflammatory genes in CHIT1-
OE BMDM when compared to control BMDM. N=3, values represent fold change in transcript abundance. 
In order to better understand the effects of CHIT1 overexpression, a cytokine antibody array was 
performed using nitrocellulose membranes spotted with capture antibodies for a variety of cytokines and 
chemokines. The assay analyzed cell lysates prepared from BMDM, treated with the same inflammatory 
stimuli used in qPCR experiments. Membranes were incubated with cell lysates from both CHIT1-OE 
BMDM and control BMDM for 8 hours prior to application of biotin-labeled detection antibodies.  Results 





























(the murine homolog of IL-8) which is involved in immune cell recruitment, macrophage phagocytosis, 
parasitic invasion defense, and is expressed during both M1 and M2 inflammatory conditions [120-123]. 
 
Figure 10: CHIT1 overexpression alters macrophage protein expression  
Protein expression in CHIT1-OE BMDM and control BMDM was detected with a mouse cytokine array. 
Cell lysates were prepared from experimental and control BMDM which were untreated or exposed to 
20 ng/mL IFN-γ + 100 ng/mL LPS for 8 hours. (A-C) BMDM treated with pro-inflammatory stimuli 
exhibited a significant increase in protein expression of (A) G-CSF, (B) KC, and (C) IL-4. N=3 biological 
replicates, each run in duplicate. Values represent fold change in florescence. *p<0.05, **** p<0.0001 
 
3.2.2 Inflammatory signaling pathways are inhibited by CHIT1 overexpression 
Phosphorylation is a fundamental component of intracellular signal transduction. To further 
explore the cell signaling potential of CHIT1, we treated both CHIT1-OE and control BMDM with IFN-γ + 






















phosphorylated signaling molecules: ERK 1/2, Akt, and IκB. While pIκB was not changed, pAkt (ser) and 
pERK 1/2 (ser) was significantly down regulated depicting a decrease in phosphorylated signaling in this 
pathway. This is consistent with diminished transcription of pro-inflammatory cytokines that we observed 
(figure 11C-D).   
 
Figure 11: CHIT1 overexpression affects signaling pathways in macrophages 
BMDM from CHIT1-OE mice and control animals were treated with 20 ng/mL IFN-γ + 100 ng/mL LPS for 0, 
0.5, and 1 hour. (A) Cell lysates were incubated with florescent antibodies for phosphorylated signaling 
molecules, and analyzed with Western blot. Florescence intensity was measured using the Licor Odyssey 
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stimuli led to depressed ERK1/2 signaling in CHIT1-OE BMDM after 0.5 hour and (D) Akt signaling after 
one hour when compared to control BMDM. N=3 *p<0.05 **p<0.01,   
 
3.2.3 Macrophage invasiveness is enhanced by IL-13 in CHIT1 overexpressing macrophages 
Infiltration of immune cells is facilitated in part by chemoattractants. MCP-1 is widely recognized 
as a macrophage chemoattractant that promotes invasion through the endothelium and plays a significant 
role in macrophage invasion of atherosclerotic plaques. A transwell invasion assay was performed to 





Figure 12: Macrophage invasiveness is enhanced by IL-13 in CHIT1-OE BMDM 
A transwell invasion assay was performed with ECM matrigel serving as a basal substrate over a 0.8 µm 
membrane within the transwell insert. (A) BMDM from control mice and CHIT1-OE mice were seeded on 
the matrigel and were treated with 10 ng/mL IL-13 or left untreated for 24 hours. Cells that migrated to 
the underside of the membrane were stained with crystal violet and quantified. (B) While CHIT1 expression 









































CHIT1-OE BMDM treated with IL-13. (B) Crystal violet staining was quantified using ImageJ software as % 
area stained compared to total area. N=3, *P<0.05 **P<0.01 
CHIT1-OE and control BMDM were seeded onto a layer of ECM matrigel in the top chamber of 0.8 
µm filter membranes and allowed to migrate overnight in the presence of different chemoattractants. As 
an experimental control, MCP-1 was added to the bottom chamber of the transwell. IL-13 was explored 
as a possible chemoattractant due to its putative non-enzymatic interactions with CHIT1 (figure 12A). 
After 24 hours, the infiltrated cells were stained on the underside of the insert membrane with crystal 
violet. The images were analyzed with ImageJ software to quantify the macrophages that invaded the 
matrigel (figure 12B). No significant difference in invasiveness was detected with MCP-1. However, with 
IL-13 as the chemoattractant, CHIT1-OE BMDM displayed a significant increase in macrophage invasion in 
contrast to control BMDM. 
3.2.4 Cholesterol metabolism was not affected by CHIT1 overexpression in BMDM 
Uptake and efflux of low-density lipoproteins (LDL) by macrophages are extremely important 
mechanisms that have a profound effect on inflammation, foam cell formation, plaque development, etc.  
In direct lipid uptake experiments, we conducted a lipid uptake assay by incubating macrophages from 
CHIT1-OE mice and littermate controls with DiI-labeled, acetylated LDL or oxidized LDL for 6, 12, and 24 
hours. Levels of cellular LDL accumulation were measured with flow cytometry by detection of the mean 
fluorescence intensity (MFI) of DiI. figure 13 shows MFI values for both conditions in experimental and 









Figure 13: Macrophage overexpression of CHIT1 does not affect the lipid uptake in vitro 
BMDM from CHIT1-OE mice and littermate controls were either left untreated or stimulated with 20 ng/mL 
IFN-γ + 100 ng/mL LPS and incubated with (A) DiI-labeled ox-LDL or (B) Ac-LDL for 6 hours, 12 hours or 24 
hours. The lipid uptake was measured with flow cytometry. No significant difference was observed 
between groups. N=3 
Proper regulation of cholesterol efflux in macrophages is imperative to cellular homeostasis and 
biological function. Further, dysfunctional cholesterol efflux is fundamental to the development and 
progression of atherosclerosis as lipid accumulation leads to deleterious downstream effects. To 
investigate whether overexpression of CHIT1 in BMDM affects transcription of genes involved in lipid 
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metabolism, we employed qPCR analysis (figure 14). Treatment of BMDM from CHIT1-OE mice with 
acetylated LDL (ac-LDL) for 6 hours resulted in diminished transcription of ABCA1 mRNA and enhanced 
transcription of ABCG1 compared to control BMDM In vitro. We utilized a cholesterol efflux assay to 
investigate whether CHIT1 overexpression affects cholesterol homeostasis by labelling Ac-LDL with [3H]-
cholesterol and incubating BMDM from CHIT1-OE and control mice for 24 hours. While we observed 
significant differences in ABCA1 and ABCG1 transcription (figure 14A and B), cholesterol efflux was not 





Figure 14: Overexpression of CHIT1 does not affect cholesterol efflux 
mRNA transcription of genes involved with macrophage cholesterol efflux was determined using qPCR. 
BMDM from control and CHIT1-OE mice were incubated with or without Ac-LDL for 6 hours. (A) 
Transcription of ABCA1 was significantly down regulated in CHIT1-OE BMDM incubated with Ac-LDL. (B) 
ABCG1 transcription was significantly upregulated when CHIT1-OE BMDM were exposed to Ac-LDL in 
comparison to control BMDM. (C) PPARγ was not significantly affected by treatment with Ac-LDL in either 
experimental or control BMDM. (D) Cholesterol efflux was carried out by incubating BMDM from CHIT1-
OE and control mice with [3H]-Cholesterol-labeled Ac-LDL for 24 hours. Efflux was generally unchanged 
between groups. N=3, *P<0.05 
3.3 Macrophage overexpression of CHIT1 affects atherosclerotic plaque morphology in vivo 
Taken together, in vitro data that CHIT1 inhibited transcription of pro-inflammatory cytokines and 



































invasion of ECM are suggestive of a protective role for CHIT1 in atherosclerosis. To test whether our in 
vitro data indeed support this assertion, an atherosclerosis mouse study was designed. For this in vivo 
model we crossbred Ldlr-/- mice with CHIT1-OE mice in order to generate an atherosclerosis-prone, CHIT1 
overexpressing mouse model. After 8 weeks male mice were placed on HFD containing 15.8% (wt/wt) fat 
and 1.25% cholesterol (wt/wt) (diet 94059; Harlan Teklad Laboratories, Indianapolis, IN, USA) for 12 weeks 
to induce atherosclerosis. 
3.3.1 Initial characterization of Ldlr-/-- CHIT1-OE mice post-HFD 
Upon termination of the HFD regimen, blood was collected from all study mice in each group 
before sacrifice. Serum cholesterol and triglyceride levels were analyzed with commercially available 
fluorometric and colorimetric kits (Cayman Chemical). No difference in cholesterol or triglycerides was 
detected between experimental and control groups. Measurement of body weight before and after 12 
weeks of HFD revealed significant weight gain in both groups at the end of the experiment, with no 




Figure 15: Initial characterization of study mice 
After 12 weeks of HFD both control mice and Ldlr-/-- CHIT1-OE mice were analyzed for differences in serum 
triglycerides and cholesterol levels. (A-B) Using a colorimetric and fluorometric kit revealed no significant 
differences in serum triglycerides or cholesterol between groups. (C) Animal body weight was also 
measured before and after administration of HFD. No significant differences were observed between 







Analysis of circulating leukocyte populations following 12 weeks of HFD was carried out using flow 
cytometry. 100 µL of whole blood was stained with antibodies specific to flow cytometry as previously 
described. Figure 15 depicts leukocyte populations of T cells, monocytes, and neutrophils (figure 16). No 
significant difference in these populations was observed between groups suggesting that CHIT1 does not 
affect leukocyte survival or proliferation. 
Figure 16: Populations of circulating leukocytes after 12 weeks of HFD 
Blood collected from study mice at sacrifice was processed, stained, and analyzed using flow cytometry in 
order to determine the relative percentage of each population compared to viable/CD45+ cells. (A-D) 
Monocytes, neutrophils, CD4 T cells, and CD8 T cells were identified via differential gating based on 









3.3.2 CHIT1 overexpression in atherosclerotic mice does not affect plaque area 
 Areas of the cardiovascular system that are subject to high flow volumes and shear stress for 
vulnerable regions for the development of atherosclerotic plaque. The aortic sinus, aortic arch, and 
abdominal aorta are widely accepted as being indicative of atherosclerosis in vivo. In an effort to 
determine the effects of CHIT1 overexpression in Ldlr-/- mice, mouse hearts were perfused with 4% 
PFA/5% sucrose before being removed from the animal. Hearts were subsequently embedded in OCT 
compound, and frozen at -80° C. Serial cryosections were prepared at a thickness of 10 µm using a 
cryostat, and were then mounted on to glass slides. Cryosections were made specifically of the aortic sinus 
where all 3 leaflets are visible. Samples from both groups were stained in ORO for 30 minutes before being 
washed with 60% isopropanol (figure 17A). Quantification was performed using ImageJ software and 
measurements are represented as the percentage of stained area in relation to total plaque area (figure 
17B). To further analyze plaque content in vivo we also quantified plaque accumulation in the whole aorta. 




Figure 17: Aortic plaque size is not affected by CHIT1 overexpression in vivo 
(A) Cryosections of the aortic sinus from both Ldlr-/-- CHIT1-OE (CRE+) mice and littermate controls (CRE-) 
after 12 weeks of HFD were stained with Oil-Red-O to determine plaque size. (B) Analysis of plaque area 
as a function of % total area. Measurement with ImageJ software showed no significant differences in 
plaque size between experimental and control animals. N=14 per group 
 
An incision was made longitudinally along the length of the aorta such that it could be separated, pinned, 
and stained with ORO for 30 minutes (figure 18A). Again, plaque aggregation was measured with ImageJ 
software and in this case results are represented as percentage of stained area in relation to total aortic 









Figure 18: CHIT1 overexpression by macrophages does not affect aortic atherosclerotic lesion size 
(A) Whole aortas were removed from both Ldlr-/--CHIT1-OE and control mice after 12 weeks of HFD. The 
specimens were pinned and stained with Oil-Red-O. (B) No difference was observed between groups upon 



















3.3.3 Macrophage content in atherosclerotic plaques is unaffected by CHIT1 overexpression 
 Macrophages play multifaceted roles in the development of atherosclerosis. Recruitment and 
accumulation of macrophages is associated with increased plaque size and weakening of the fibrous cap. 
We sought to determine whether CHIT1 overexpression in Ldlr-/- mice alters macrophage accumulation in 
atherosclerotic plaques. To this end, slides were prepared from serial cryosections of the aortic sinus at 
10 µm increments. Figure 19 depicts samples from each group that were incubated for 24 hours with 
MOMA primary antibody and then and HRP conjugated chromogen was applied. MOMA is a macrophage 
specific stain and therefore, it was utilized to determine macrophage content and plaques. No significant 
difference was observed between groups after analyzing percent MOMA stained area relative to total 






Figure 19: Macrophage content in aortic plaques is not affected by CHIT1 overexpression in vivo 
(A) Cryosections of the aortic sinus from both Ldlr-/-- CHIT1-OE mice and littermate controls after 12 weeks 
of HFD were stained with MOMA to determine macrophage content. (B) Analysis of stained area versus 
% total plaque area. Measurement with ImageJ software showed no significant differences in macrophage 



















3.3.4 CHIT1 is highly expressed in atherosclerotic plaques of Ldlr-/--CHIT1-OE mice post-HFD 
 Given the importance of macrophages in every stage of atherosclerosis and the fact that CHIT1 is 
among the most abundantly expressed proteins by activated macrophages, we stained serial cryosections 
prepared at a thickness of 10 µm of the aortic sinus with a murine CHIT1 antibody (figure 20). Ensuing 24 
hours of incubation, a secondary HRP conjugated chromogen was applied and CHIT1 was visualized using 
light microscopy. IHC revealed significantly greater expression of CHIT1 in the atherosclerotic plaques of 
Ldlr-/-- CHIT1-OE mice in comparison to littermate controls. CHIT1 staining was quantified using ImageJ 










Figure 20: CHIT1 is abundant in atherosclerotic plaques of Ldlr-/--CHIT1  
(A) Cryosections of the aortic sinus from both Ldlr-/-- CHIT1-OE mice and littermate controls after 12 weeks 
of HFD were stained with biotinylated antibodies against CHIT1. (B) Analysis of stained area versus % total 
plaque area. Measurement with ImageJ software showed no significant differences in macrophage 

















3.3.5 CHIT1 overexpression alters ECM content in the aortic sinus of Ldlr-/- mice 
At sacrifice, mice were perfused with PBS followed by 4% PFA/5% sucrose. The hearts were 
collected and embedded in OCT compound to be frozen and cryosectioned at a thickness of 10 µm. Serial 
sections were made at the aortic sinus where 3 valve leaflets were visible. The heart sections were stained 
for hyaluronic acid (HA) using a biotinylated hyaluronic acid binding protein (BHABP) and collagen using 
picrosirius red. The sections were analyzed using ImageJ software to determine the area of HA and 
collagen deposition as a percentage of overall plaque area (Figure 21). Our findings were that both HA 
and collagen were significantly more abundant in CHIT1 overexpressing mice. 
Figure 21: CHIT1 overexpression significantly increases HA and collagen in atherosclerotic plaques 
(A-B) Analysis of stained collagen and HA area as a function of % total plaque area. Measurement with 
ImageJ software revealed significant differences in collagen stained area between experimental and 
control animals. HA: N=6 per group, Collagen: N=7 per group 
 
Further, the pattern of HA and collagen accumulation had observational differences in distribution 
between CHIT1-OE mice and littermate controls (figures 22 and 23). We found that while HA expression 
was generally limited to the periphery of atherosclerotic plaques in control mice, while in CHIT1-OE mice 







Figure 22: Overexpression of CHIT1 alters the distribution of HA in atherosclerotic plaques 
(A and D) antibody control. (B and E) HA stained with BHABP can be seen localized in the periphery of the 
aortic sinus in control cryosections, whereas HA appears throughout the plaque and within the necrotic 
cores of Ldlr-/-- CHIT1-OE mice. (C and F) 10 X magnification reveals the extensive HA staining in plaques 
of Ldlr-/-- CHIT1-OE mice particularly within the necrotic core. N=6 per group 
 
 







Distribution of collagen in plaques from control mice was similar to that of HA, whereas in CHIT1-OE mice 
collagen staining was most prevalent on the luminal aspect of atherosclerotic plaques and could be found 
encircling necrotic cores (figure 23). 
 
Figure 23: CHIT1 overexpression augments collagen distribution in atherosclerotic plaques 
(A) Cryosections of the aortic sinus from both Ldlr-/-- CHIT1-OE mice and littermate controls after 12 weeks 
of HFD were stained with picrosirius red to visualize type I collagen. While collagen appears unorganized 
and lightly stained especially on the luminal aspect of necrotic cores in control sections, collagen had a 
more organized “lattice” appearance and was distributed around necrotic cores and specifically on the 














CHAPTER 4: DISCUSSION 
 
4.1 Summary and interpretation of results 
In previously published work, we reported that CHIT1 mRNA was present in atherosclerotic lesions 
within the descending aorta of cynomolgus monkeys. CHIT1 mRNA expression was also closely correlated 
with macrophage infiltration in atherosclerotic plaques of abdominal aortas. Our research further 
demonstrated that inhibition of CHIT1 with allosamidin promoted atherosclerosis in hyperlipidemic mice 
[119]. Here we show In vitro evidence using CHIT1-OE macrophages that overexpression of CHIT1 
modulates the inflammatory response in an anti-inflammatory manner when subjected to an 
inflammatory stimulus of IFN-γ with LPS. A non-resolving inflammatory response promotes the 
development of atherosclerosis through continuous recruitment and activation of immune cells, perhaps 
most importantly, macrophages. As CHIT1 is abundantly produced by activated macrophages, it is likely 
that it’s expression contributes to anti-inflammatory cell functions. Macrophage invasion through the 
ECM was also quantified in vitro and revealed that IL-13 significantly enhanced the invasiveness of CHIT1-
OE BMDM.  In developing a Ldl-/-- CHIT1-OE mouse model we were able to conduct an in vivo mouse study 
to investigate the effects of CHIT1 overexpression in an atherosclerotic animal model. While we were 
unable to observe significant differences in macrophage content or lesion size, we found significant 
alterations in plaque morphology. The accumulation and distribution of HA and collagen allude to a 
possible interaction between CHIT1 and the ECM. 
4.1.1 Macrophage inflammatory functions 
Dysregulation of the innate immune response drives atherogenesis, and the resultant stages of 
atherosclerosis are largely attributable to the recruitment and infiltration of monocytes into the intimal 
layer of the vessel wall. Chemokines like macrophage chemoattractant protein-1 (MCP-1) are well known 
contributors to atherosclerosis [124, 125]. MCP-1 has been shown to accelerate atherosclerosis in ApoE-
deficient mice. MCP-1 overexpression in ApoE-deficient mice resulted in increased to lipid staining, 
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oxidized lipid, and immunostaining for macrophage cell surface markers. Our own experiments revealed 
a trend of transcriptional down-regulation of MCP-1 in CHIT1-OE BMDM compared to littermate controls 
when exposed to IFN-γ with LPS. Given the importance of MCP-1 in the development of atherosclerotic 
plaques and disease progression, the relationship it shares with CHIT1 expression is certainly intriguing. 
Recruitment of macrophages toward atherosclerotic lesions and plaques is effectively achieved in large 
part by the chemoattractant properties of specific cytokines. Interestingly, we found protein expression 
of the chemotactic cytokine KC (the murine homolog of IL-8) is significantly upregulated in CHIT1-OE 
macrophages when treated with inflammatory stimuli. KC and its receptor CXCR2 are secreted by 
activated macrophages and play a significant role in immune cell trafficking and infiltration of the vessel 
wall. In an effort to elucidate the mechanism of KC/CXCR2 in atherosclerosis, Boisvert et al. utilized LDLR-
/-, atherosclerosis-prone mice with KC/GRO-α-/- and CXCR2-/- mice to demonstrate that overexpression of 
KC/GRO-α and CXCR2 are essential to macrophage accumulation into atherosclerotic lesions. Results also 
revealed that KC/GRO-α and CXCR2 do not play a critical role in macrophage recruitment into early 
atherosclerotic lesions [126]. While it is generally accepted that KC participates in development of 
atherosclerosis, other studies suggest a putative role of IL-8/KC in smooth muscle cell proliferation and 
recruitment as well as angiogenesis [127-129]. IL-8 was shown to be a potent macrophage-derived 
mediator of angiogenesis. Human recombinant IL-8 was administered in the rat cornea where it induced 
proliferation and chemotaxis of human umbilical vein endothelial cells. Also, blockade of IL-8 by antibodies 
decreased angiogenic activity of inflamed human rheumatoid synovial tissue macrophages [130]. Such 
findings suggest that IL-8 may be involved in tissue repair and wound healing.  
IL-4 is a cytokine associated with alternative macrophage activation which potentiates Th2 
inflammatory processes. We have demonstrated that IL-4 protein expression is significantly upregulated 
in CHIT1-OE BMDM. Experimental evidence demonstrates that IL-4 signaling involves SOCS1 to induce M2 
macrophage polarization while inhibiting SOCS3 signaling and negatively regulating M1 polarization [131, 
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132]. IL-4 activation of alveolar macrophages has been shown to promote wound healing in the long after 
Helmand invasion or during gut inflammation in mice [133]. And in the context of atherosclerosis, IL-4 
attenuated atherosclerosis in several different mouse models [134-136]. Given that IL-4 and IL-13 
signaling includes a pathway requiring both cytokines, and the putative interactions of CHIT1 with IL-13, 
it is foreseeable that CHIT1 can participate in IL-4/IL-13 signal transduction. 
A definitive role for macrophage-derived granulocyte colony stimulating factor (G-CSF) in 
atherosclerosis has yet to be established. However, several studies suggest protective roles for G-CSF in 
atherosclerotic animal models. We observed a significant increase in protein expression of G-CSF in 
BMDM harvested from CHIT1-OE mice compared to WT controls. Experiments with human peripheral 
blood mononuclear cells (PBMC) illustrated that G-CSF post-transcriptionally inhibits TNF-α secretion from 
PBMC. Suppression of TNF-α secretion was accomplished without affecting mRNA expression [137]. G-
CSF also promotes generation of type-1 regulatory T cells (Treg) that secrete the anti-inflammatory 
cytokine IL-10, and TGF-β1 which is associated with tissue repair, wound healing, and fibrosis [138].  
Several studies have described a protective role for G-CSF in atherosclerotic mouse and rabbit models. 
Daily treatment of ApoE deficient mice with G-CSF for nine weeks resulted in less atheromatous plaque 
area and a decrease in macrophage infiltration into atherosclerotic lesions. The authors also observed 
decreased serum cholesterol and LDL, which is suggestive of lipid-related effects of G-CSF [139]. In 
hyperlipidemic and cholesterol fed rabbit models, G-CSF administration prevented progression of 
atherosclerotic lesions and vascular stenosis, while encouraging plaque stability and reendothelialization. 
Moreover, it was shown that an appropriate dosage of G-CSF was required for these protective effects to 
manifest most efficiently [140, 141]. 
Pro-inflammatory cytokines like TNF-α and IL-6 perpetuate chronic inflammation associated with 
atherosclerosis. We found that transcripts of both were down regulated in BMDM from CHIT1-OE mice 
compared to those of littermate controls, in vitro, when stimulated with a combination of the 
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inflammatory stimuli; IFN-γ + LPS. TNF-α is a potent mediator of inflammatory signaling by influencing the 
activation state of leukocytes, the release of cytokines and chemokines, and expression of NO and ROS. 
Studies have indicated that TNF-α contributes to the development and progression of atherosclerosis. 
Using a TNFα-deficient mice crossbred with atherosclerosis prone APOE*3-Leiden mice, Boesten et al. 
demonstrated that TNF-α promoted the formation of advanced lesions and necrosis as apoptosis was 
decreased, although lesion area did not change [142]. Inhibition of TNF-α in ApoE deficient mice resulted 
in a 50% reduction of relative lesion size after 10 weeks of Western diet. And in ApoE knockout mice, 
administration of soluble TNF receptor I pellets reduced lesion size after 25 weeks [143]. 
IL-6 is another cytokine that contributes to propagating the inflammatory cascade associated with 
atherosclerosis. IL-6 modulates both acute and chronic inflammation. IL-6 is pleiotropic in nature and can 
enhance the given polarization state of macrophages. IL-6 is also capable of inhibiting Treg formation 
[144]. Injection of supra-physiological levels of IL-6 exacerbated early atherosclerosis in ApoE-deficient 
mice fed a high-fat diet. Upon injection, significant increases in IL-1β and TNF-α. Treatment with IL-6 
resulted in increased lesion size in atherosclerotic, ApoE-deficient mice. The authors concluded that the 
presence of IL-6 ultimately exacerbated early atherosclerosis in mice [145]. The effect of CHIT1 in 
diminishing transcription of inflammatory cytokines like TNF-α and IL-6 require further study to determine 
what therapeutic potential if any may exist. 
4.1.2 Inflammatory signaling pathways 
To extend our understanding of the inflammatory mechanisms affected by CHIT1 overexpression, 
we investigated inflammatory signaling pathways associated with atherosclerosis. Our data revealed 
significant decrease in pERK1/2 protein expression in BMDM from CHIT1-OE mice compared to littermate 
controls when exposed to IFN-γ + LPS after 30 minutes in vitro. We also observed that Akt signaling was 
suppressed in CHIT1-OE BMDM after 60 minutes of treatment with the same inflammatory stimuli in vitro. 
The ERK1/2 signaling pathway is critical to the expression and secretion of various downstream effectors 
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that mediate inflammation. Experimental evidence demonstrates that LPS stimulation of murine 
peritoneal macrophages activated ERK1/2 signaling, causing the subsequent induction of TNF-α secretion 
[146]. IFN-γ stimulation of this pathway in human macrophages induced alterations in the expression of 
several key genes implicated in the progression of atherosclerosis, such as MCP-1 [147]. Akt signaling has 
various roles in macrophage function. Deficiency of Akt mediated signal transduction elicits M2 
macrophage polarization and negative regulation of the TLR4 signaling pathway [148-150]. In relation to 
atherosclerosis, Zhai et al. found that inhibition of Akt signaling depressed autophagy in vitro, and 
atherosclerotic mouse models exhibited enhanced plaque stability as well as diminished inflammatory 
response was promoted by Akt/mTOR-mediated autophagy [151]. 
4.1.3 Macrophage invasion 
Invasion of monocytes/macrophages is a continuous process throughout atherosclerosis that 
begins with the initiation of an inflammatory response by invading monocytes, illicit plaque formation via 
infiltration and accumulation of immune cells, and ultimately ends with fibrous cap weakening and 
thrombosis. Given the data presented in a number of studies describing the effects of CHIT1 and IL-13, we 
performed an ECM invasion assay to determine whether this interaction influences macrophage 
invasiveness [115, 152, 153]. We found that when IL-13 was used as a macrophage chemoattractant, 
invasion of CHIT1-OE BMDM through the ECM matrigel was significantly greater than those from 
littermate controls. Interestingly, Correale et al. showed that IL-13 significantly increased CHIT1 secretion 
from macrophages and that CHIT1 enhanced macrophage secretion of chemokines including IL-8, MCP-1, 
and RANTES. Further, IL-13 promoted macrophage transmigration through a blood-brain barrier model in 
vitro [115]. Induction of immune cell trafficking by CHIT1 in concert with IL-13 seems to be a novel 
interaction that may have relevant effects in atherosclerosis and other inflammatory diseases. 
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4.1.4 Overexpression of CHIT1 and atherosclerotic plaque morphology 
The ECM is an important component for a wide array of cellular functions. In the cardiovascular 
system, ECM interactions serve as a cell signaling platform and maintain structural integrity of the heart 
and vasculature. Changes in ECM content related to atherosclerosis has been implicated in fibrous cap 
formation and plaque stability. Our results demonstrate a significant increase in key ECM components: 
hyaluronic acid (HA) and collagen in the plaques of ldlr-/-, CHIT1-OE mice when compared to littermate 
controls. HA is a large, hydrophilic glycosaminoglycan (GAG) that is integral to wound healing and tissue 
remodeling [154]. Degradation of HA by hyaluronidases is upregulated in unstable atherosclerotic 
plaques, while the formation of a pericellular HA matrix supports smooth muscle cell proliferation and 
migration possibly enhancing plaque stability [155, 156]. It should be noted that no endogenous substrate 
for CHIT1 has been identified in vertebrates. However, studies have demonstrated that the DG42 gene in 
Xenopus and mouse models produces chitin-oligosaccharides as a precursor to HA chains [157, 158]. Also, 
due to the structural similarity of HA to its native substrate; chitin, the CHIT1 binding domain is capable 
of interactions with HA [107, 108]. It may be possible that chitin interactions with HA prevent its 
degradation, thereby promoting plaque stability. 
Like HA, collagen contributes to the mechanical strength of atheromatous plaques. Collagen 
comprises up to 60% of the total plaque protein and engages a multitude of cell functions. Modulation of 
macrophage behavior, smooth muscle cell proliferation/migration, and plaque reinforcement exemplify 
the variety of functions and cell types that collagen can influence [159-161]. CHIT1 has also been 
implicated in collagen production as evidenced by fibrotic diseases in the liver and lungs. Interstitial lung 
disease with pulmonary fibrosis is representative of pulmonary systemic sclerosis. CHIT1-/- murine models 
demonstrate reduced fibrosis, and in vitro studies showed that CHIT1 interactions with TGF-β1 augment 
the expression of both TGF-β 1 and 2 receptors and subsequent TGF-β-induced ERK activation [113]. 
Human Kupffer cells were also implemented to investigate the role of CHIT1 in nonalcoholic 
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steatohepatitis. This data highlighted the ability of CHIT1 to activate hepatic stellate cells which, in turn, 
results in the overproduction of collagen and ultimately hepatic fibrosis [114]. 
In our assessment of plaque morphology, despite having no difference in macrophage content or 
size, collagen and hyaluronic acid deposition was markedly different between experimental and control 
animals. Ldlr-/--CHIT1-OE mice on an atherosclerotic diet,  displayed hyaluronic acid staining throughout 
the plaque and around necrotic cores, whereas aortic sections from control mice showed accumulation 
of hyaluronic acid around the periphery of the vessel. Collagen staining revealed substantial accumulation 
on the luminal aspect of necrotic cores in Ldlr-/--CHIT1-OE animals. In contrast, collagen distribution in 
control animals did not show any particular patterning in atherosclerotic plaques. Taken together, 
overexpression of CHIT1 by macrophages augments ECM biosynthesis and organization in such a way that 
enhances plaque stability in Ldlr-/--CHIT1-OE  mouse models. 
4.2 Limitations and future directions 
The data presented in this dissertation provide novel insight into the non-enzymatic signaling 
properties of CHIT1 in atherosclerosis. Macrophage overexpression and secretion of CHIT1 augmented 
the inflammatory response of BMDM exposed to inflammatory stimuli in vitro. CHIT1 overexpression in 
ldlr-/- mice resulted in alterations to ECM deposits and plaque morphology in vivo. In lieu of our previously 
published findings which demonstrated that inhibition of chitinase promotes atherogenic macrophage 
function in vitro and promotes atherosclerosis in ApoE-/- mice [119], we sought to understand the 
mechanism and therapeutic potential of CHIT1 overexpression in atherosclerosis. One underlying caveat 
in the comparison of our previous data is that chitinase inhibition was achieved through dietary 
administration of allosamidin; a competitive inhibitor of all chitinases that also binds to chitinase-like 
proteins (CLP). Chitinases and CLPs both contain a glycosyl-18 domain which is evolutionarily conserved 
among the 18 glycosyl hydrolase family. In the case of CLPs, mutations in the highly conserved enzymatic 
sites render them enzymatically inactive and thus they are also termed chitolectins. Despite their lack of 
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enzymatic activity, CLPs are still able to bind chitin through conformational changes dependent on the 
oligosaccharide length in the same fashion as true chitinases [162]. Breast regression protein-39 (BRP-39) 
and its human homolog YKL-40 (Chi3l1) are CLPs that are expressed in a variety of cells including 
macrophages, neutrophils, and vascular smooth muscle cells. YKL-40 has been shown to inhibit cellular 
responses to pro-inflammatory cytokines IL-1 and TNF-α [163]. YKL-40 is also able to bind specifically to 
type I collagen, modulating the rate of fibril formation [164]. Other studies have indicated that the CLPs: 
YM1 and YM2 alternatively activate macrophages, initiating Th2-mediated inflammation [165]. The 
authors went on to show that macrophages can express M2 surface markers upon activation with CLPs 
independently of neutrophils. In many ways, the very existence of CLPs is confounding and enigmatic. 
However, it has become clear that both true chitinases and CLPs have signaling properties beyond any 
enzymatic capacity. Furthermore, their abundant secretion as a part of both M1 and M2 macrophage 
polarization suggests varying roles for these molecules. 
CHIT1 overexpression has been described in a number of chronic conditions affecting different 
tissues and organ systems. These include: lysosomal storage disorders like Niemann-Pick’s and Gaucher’s 
disease [166], asthma and airway inflammation/remodeling [153, 167], and non-resolving inflammatory 
diseases like diabetes, atherosclerosis, and liver disease [118, 168, 169]. And although the non-enzymatic 
interactions of CHIT1 are poorly understood, the close association it has with sterile inflammation and 
tissue remodeling in the absence of an endogenous substrate make it an intriguing target for augmenting 
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